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Abstract 
This thesis is devoted to the synthesis of new chelating agents for actinium and 
actnoids (An), as part of a research effort to the production of new radio immune 
drugs. 
The first part is dedicated to the synthesis of the first member of a brand new class 
of An chelating agents based on dendrimers. These compounds are particular 
interesting because they can give drugs with an higher dose load (i.e. with more 
than one An atom bound by the same chelating agent), extremely difficult to be 
realized with traditional methodology. The identified target molecule is benzoyl-
(Glu)G3-OEti a dendrimer of glutamic acid.  When this thesis started there was no 
article or hypothesis at all on the complexing properties of dendrimers towards 
An, but very recently the chelating properties of dendrimers towards uranium 
have been assessed. Although this takes away the primogeniture of the idea, it 
supports the validity and interest of this research field. 
The second part is dedicated to the synthesis of new nitrogenated chelating agents. 
New synthetic ways for the synthesis of N-nitroso compounds are inspected. These 
species have been chosen by using one of the synergic strategies nowadays so widely 
recommended in industrial management manuals. In fact their complexing properties 
toward transition metals and lanthanoids are well known and it is of scientific and 
applicative interest to synthesize new suitable chelating agents to make possible the 
study of their chelating affinity towards An. At the same time, they can be used as both 
starting material for the synthesis of hydrazinic chelating agents and synthetic 
scaffolds for the synthesis of a wide range of pendant-type-macrocyclic 
bifunctionalised chelating agents . 
The third part is dedicated to the identification of new synthetic pathway towards 
classical pendant-type macrocyclic bifunctionalised chelating agents. A lot of 
syntheses have been published on this argument, both cumbersome and with low 
yields. The basic idea of this work was to avoid the total ring synthesis by exploiting  
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the well-known acidity of proton in α position with respect to a nitroso group. 
Unluckily, this kind of approach did not give any result, probably because of 
conformational problems. Also other attempts of direct introduction of a pendant on a 
functionalized ring performed with several different basis and activating agents, did 
not bring to the desired products.  
Since all previous attempts were unsuccessful, an optimization of the classical 
total ring synthesis focused on the cyclisation step (that all authors performed under 
extreme diluted conditions with very low yields) has been enquired. 
In conclusion, during the work of this thesis the first member of a brand new class 
of possible chelating agents has been synthesized along with new potential 
macrocyclic chelating agents containing hydrazine and N-nitroso substituted nitrogen 
atoms. Literature does not report any suitable gram scale synthesis of pendant-type 
macrocyclic chelating agents, either by using N-nitroso macrocyclic chelating agents 
as starting materials or by performing the total ring synthesis. Evaluation of the actual 
An chelating properties of the synthesized molecules is well beyond the scope of this 
thesis and can only be investigated in a facility suited to work with highly radioactive 
isotopes. 
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Part I 
State of the Art 
  
 
Chapter 1 
 
Radioimmunotherapic Drugs 
 
1.1 General concepts 
 
Aim of this work is the synthesis of BCA, the molecular moiety in RIT and RID 
drugs that bind together the antibody (that seeks for cells that express the related 
antigen) and the radioactive isotope (whose decay will kill the malignant cells). 
Immunotherapeutic and immunodiagnostic drugs, whose characteristic is 
their ability to selectively recognize and bind to specific targets, have been 
proposed at the beginning of last century by Paul Herlichii. He suggested the 
side chain theory for antibody and antigen interaction just seven years after the 
discovery of antibodies in 1890, when Emil von Behring and his student 
Shibasaburo Kitasato described their activity against diphtheria and tetanus 
toxins. In this theory he hypothesized that receptors (described as “side chains”) 
on the surface of cells could bind specifically to toxins – in a "lock-and-key" 
interaction – and that this binding reaction was the trigger for the production of 
antibodies, Fig. 1.1. 
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Errore. L'origine riferimento non è stata trovata. 
Fig. 1.1: Antibody and lock-and-key interaction with its antigen 
The next logical step was to imagine, like he made in 1904, to use this 
natural pointing system to address substances that can induce cellular apoptosis 
into cancer cells and other pathogens, i.e. immunotherapeutic drugs. 
Since the global performance of these drugs and their viability are 
determined by each of its moiety and each part interacts with the other two, it is 
important -before to begin any research in this field- to understand their basic 
functioning and the restraining condition they pose each other.  
1.2  Monoclonal antibodiesiii 
An immune system is a collection of mechanisms within an organism that 
protects it against disease by identifying and killing pathogens and tumor cells. 
It detects a wide variety of agents, and needs to distinguish between organism's 
own healthy cells and tissues (self) and foreign substances (non-self) in order to 
function properly. Detection is complicated as pathogens adapt and evolve new 
ways to disguise themselves and successfully infect the host organism. 
To survive this challenge, more and more sophisticated mechanisms have 
evolved that recognize and neutralize pathogens. Even simple unicellular 
organisms such as bacteria possess enzyme systems that protect against viral 
infections. More sophisticated mechanisms developed with the evolution of 
vertebrates, even if the primitive mechanisms are still operating. In the most 
evolved of these mechanism DNA of B germline lymphocytes undergoes to 
random mutations, generating millions of “clones”, each one producing a 
different kind of antibody specific for its own antigen. All this antibodies, also 
  14 
 
called immunoglobulin (Ig), have the same base structure, consisting of four 
polypeptides –two heavy chains and two light chains- joined by disulphide 
bonds to form a “Y” shaped molecule. 
 
Fig. 1.2: Antibody structure 
It is the amino acid sequence on "Y" tips, composed of 110-130 amino acids,  
that varies greatly among different antibodies and gives to each of them its 
specificity toward one antigen. The variable region includes the ends of the light 
and heavy chains. Treating the antibody with a protease can cleave this region, 
producing the so called Fragment Antigen Binding (Fab). The constant region, 
named crystallisable fragment (Fc), determines the mechanism used by the body 
to destroy the detected antigen. 
The variable region is further subdivided into hypervariable (HV) and 
framework (FR) regions. Hypervariable regions have a high ratio of different 
amino acids in a given position, relative to the most common amino acid in that 
position. They directly contact a portion of the antigen's surface. For this reason 
are also sometimes referred to as complementarity determining regions (CDR). 
Within light and heavy chains, three hypervariable regions exist, separated by 
four FR regions which have more stable amino acids sequences. 
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1.2.1  Murine Mab 
To exploit antibody for drugs an industrial scale procedure for their selection 
and production was needed. In the 70’s of last century the set up of cellular 
hybridization technique by Köhler and Milsteiniv allowed big scale production of 
Monoclonal antibody (Mab), generating a wave of scientific and economical 
enthusiasm equivalent of the unbridled optimism that nowadays surrounds stem 
cells. 
This basic production process involves injecting a specific antigen into a 
mouse, thereby inducing the mouse's B lymphocytes antibodies production. To 
harvest such antibodies, scientists would ideally pluck only the B cells that make 
them. But finding those cells and getting them to make large quantities of the 
antibodies takes some doing.  
Part of the complex procedure involves fusing B cells from the mice to 
immortalized (endlessly replicating) cells in culture to create cells called 
hybridoma. Each cell (“clone”) is bread, non immortal hybridoma dies after a 
while and (among the immortal surviving cells) those producing the required 
antibody are selected. The drawback of these particular hybridoma is that they 
produce murine antibodies, which the human immune system can perceive as 
interlopers.  
Patients who have received infusions of murine monoclonals have experienced a 
so-called Human Anti-Mouse Antibodies (HAMA) response. This syndrome 
includes joint swelling, rashes and kidney failure and can be life-threatening. It 
also destroys the antibodies. As consequence rodent antibodies cannot be used 
for prolonged human therapy: Clinical trials failed, stocks plunged and millions 
of dollars were lost. 
1.2.2  Chimerical and humanized Mab 
Several different strategies have been set up by scientist to solve this problem: 
Some point to make murine antibody more human. Since antibody specificity is 
due to interactions between its Fab region and the antigen, replacing the murine 
Fc region with a human one should not affect its specificity and reduce the 
likelihood that it is recognize as non-self by other antibodies. Some of the 
monoclonals now on sale are such chimerical –part mouse, part human- 
antibodies. Since this approach gave positive results, it was extended and more 
and more parts of the murine antibodies have been humanized.  First the FR 
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moieties of the Fab and subsequently even parts of the “CDR grafting” have 
been replaced by human counterparts. 
 
Fig. 1.3: Production of monoclonal antibodies. 
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1.2.3  Fully human Mab 
To achieve this goal investigators are attempting to mass-produce monoclonals 
without the aid of mice. Abraham Karpas of the University of Cambridge finally 
fused human B cells to human immortalized cells to create hybridoma that 
generate fully human antibodiesv. It is important to underline that this does not 
mean that no immune response from the immune system of the patient can be 
elicited, since somatic differences between antibodies of different people still 
exist. 
Another strategy entails using genetic engineering to induce mice to produce 
fully human antibodies. Mice are genetically altered to contain human antibody 
genes; injecting the mice with antigens, the animals produce antibodies that are 
human in every way. 
1.2.4  Mab by phage display 
The most promising technique called phage display not only avoids the use of 
rodents, but at the same time helps to find the most specific monoclonals against 
a particular antigen. It takes advantage of a long, stringy virus called filamentous 
phage that infects bacteria. Researchers can isolate DNA from human B 
lymphocytes, insert this DNA into bacteria such as Escherichia coli and then 
allow filamentous phages to infect the bacteria. As the phages produce new 
copies of themselves, they automatically make the proteins encoded by the 
antibody genes of the various B lymphocytes and add them to the surfaces of 
newly forming phage particles. Scientists can then use the antigen they intend to 
target, such as a receptor on cancer cells, to fish out the phages containing the 
gene for the most specific antibody to that antigen. To produce a lot of that 
antibody, they can either have one phage infect more bacteria or insert the 
antibody gene into cultured cells. 
1.3  Radionuclide 
Radioactive decay is a spontaneous nuclear transition of unstable nuclei from a 
definite quantum state of the original nuclide towards more stable nuclear 
quantum states of the daughter nuclide(s). It has been shown to be unaffected by 
pressure, temperature, chemical form, etc. This insensitivity to extranuclear 
conditions allows the characterization of radioactive nuclei (without regard to 
their physical or chemical condition) by their decay period and their mode and 
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energy of decay. All this properties have been considered for the choice of the 
most appropriate radionuclides in radioimmune drugs. 
1.3.1: Half-life 
Radioactive decay is a random process: among the atoms in an hot sample is not 
possible to identify which specific atom will be the next to decay. The number 
of disintegration per unit time A, called the decay rate, is proportional to N, the 
number of radioactive atoms present: , where λ is the 
proportional constant known as decay constant. If the number of radioactive 
nuclei and the number of decays per unit time are sufficiently great to permit a 
statistical treatment, calling A0 the activity present at some original time t=0, an 
easy mathematical treatment shows the exponential nature of radioactive decay: 
. Instead of λ is commonly used the half-live (t½), defined as the time 
required for one-half of the radioactive atoms in a sample to undergo decay (in 
practice is the time for the measured radioactivity of a sample to decrease to 
one-half of its previous value). 
In the choice of this parameter a trade-off between two opposite exigencies 
must be set. On one side drug feasible manufacturing and application require a 
long half-life. On the other side a short half-life would minimize the quantity of 
radioisotope to be given to the patient. It must be keep in mind that a big amount 
of the element would potentially deliver unnecessary doses into the environment 
–with the connected potential health damages- and increased waste 
managements  procedures.  
For biological application it must also be considered that not all the 
radioactive nuclei given to a patient decay in the body, but each kind of 
radioimmune drug (such any other substance) has its own metabolism. This 
important pharmacokinetic parameter is expressed by biological half-life (tb), 
defined as the time required for half of a given substance to be removed from an 
organism by either a physical or a chemical process. With radiopharmaceutical 
drugs both nuclear and biological half-lives must be considered, and the 
representative parameter is called effective half-life (teff): . As in 
the case of half-life a trade-off must be set in the choice of this parameter 
between the time required to the drug to reach the target and data accumulation 
on one side and kinetic of elimination on the other. A too short teff will lead to a 
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high number of disintegration before that the vector could reach the target, 
which means a bad dose ratio between the target and the health tissues. On the 
other side with a too long teff a big aliquot of the given dose would be eliminated 
from the body (usually by the kidneys) before to reach the target tissue, 
impairing the therapeutic effect. To overcome this problem a higher dose could 
be given, on the cost of a higher toxicity of health organs, kidneys in primis. 
In radiodiagnostic application the half-life is between six and a couple of 
hundreds of hours, in radiotherapeutic spans between some days and a couple of 
weeks. 
1.3.2  The dose 
Travelling trough the matter all radiations transfer their energy to the 
environment. This energy is measured by the dose, the amount of radiation 
energy absorbed per unit mass: . In the SI system it equals to 1 Joule 
per Kg and is called Gray (Gy), while in cgs system the unit was 100 time littler 
and was called rad (radiation absorbed dose). 
For biological porpoises it is 
important to know not only the whole 
quantity of energy released in the 
living, but also its density. There is in 
fact a big difference (Fig and Table ) 
in the consequence on the living if 
energy is released in tenths of meters 
(as in the case of gamma rays) or in 
some µm (as in the case of alpha 
radiations). This phenomenon is 
quantified by the linear energy 
transfer (LET), defined as the energy 
absorbed in matter per unit path 
length traveled by a radiation: 
 . 
? ?  
Fig. 1.4: Area involved in a decay event and LET  
Tab 1: Comparison between α/β decay 
 
 
Decay mode α β 
Energy [MeV] 6 1
Avarage path [mm] 0.1 5
LET  
60 0.2
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An even more accurate parameter, which considers also the dimension of the 
radioactive particles and the different nature of the living tissues that are 
travelled by radiations, is the equivalent dose, measured in Sievert (sv). 
1.3.3  Decay modes  
The mode of radioactive decay is dependent upon the particular nuclides 
involved. The energy difference between the two quantum levels involved in the 
transition corresponds to the decay energy. This decay energy appears in form of 
electromagnetic radiation and as products kinetic energy. Depending on the 
radioactive products of the process three main different decay mode have been 
identified and must be considered: α, β and γ: 
• Alpha decay is the emission of an helium nucleus. 
It is observed for elements heavier than lead and for a few nuclei as light as 
Ln. It can be symbolically written as: . As usual in 
nuclear equation X and Y indicates any element defined by its nuclear 
charge (Z and Z-2 in this case) and A is the atomic mass. 
Alpha radiations are characterized by their high energy (6-7 MeV), with a 
high ionizing power and a very short average free path -in a biologic 
medium no more than 40-80 µm. This two characteristic make α rays the 
radiation of election for immunotherapy uses on blood tumors and 
metastases, because of their high LET that kills more then 70% of the 
targeted cells with low damages on the surrounding health cells. For big 
tumor masses the short average free path results in high micro dosimetric 
effects (i.e. non homogeneous irradiation) and reduced crossfire effect (the 
irradiation of non targeted cells by radiation arising from 
radioimmunotherapic drug on neighborhood cells) the most effective death 
cause of stem cancer cells.  
• Beta decay is the emission of an electron or of its antiparticle. 
These processes include electron emission (β- or ), positron emission (β+ 
or ) and electron capture (EC). 
β- process can be written symbolically as follow: 
, where  is the antineutrino, an atomic particle 
that plays no role in this work. Like alpha particles beta ones loose their 
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energy ionizing the environment, but since they are lighter, faster and bear a 
limited electric charge they interact less with the matter. As consequence 
they have a longer average free path, from some hundreds of µm to some 
mm. It is not enough to allow these radiations to escape out of the body 
making them useful in radio diagnostic applications, but this longer path 
means less micro dosimetric effects (i.e. bigger irradiation homogeneity) and 
is enough to damage a relevant amount of cells surrounding the targeted one 
with crossfire. This is of particular relevance in dealing with tumors with 
bulky necrotic tissues, because inner malignant cells must not be directly 
targeted to cure the cancer. One of the limits of the Targeted Alpha              
Immunotherapy is in fact the need to hit directly all tumor cells. To try to 
reach this objective a quantity of drug exceeding the number of the specific 
receptors for drug Ig must be given to the patient. This excess cause 
unwonted collateral damages to other organs in general and to kidneys in 
particular. Even worse is that in the biggest number of case not all the tumor 
cells present the Ig antigens (specially the so called stem tumor cell have a 
different cell surface) and can be reached by alpha immunotherapy. To 
overcome this problem integrated alpha and beta immunotherapy protocols 
are under investigation. 
β+ processes are schemetized by the formula: , 
with basically the same interaction with matter of the former decay mode. 
Nonetheless, once the positron has been thermalised, it undergoes to an 
annihilation process with an electron giving rise to two photons of equal 
energy, 511 KeV, emitted at 180° one from the other. These photons can be 
detected in coincidence allowing separating their signal from the background 
noise allowing a better tridimensional resolution of the organs. PET vi 
(Positron Emission Tomography) is based on this effect. 
• Gamma decay is the emission of electromagnetic radiation. 
Alpha and beta decays can leave the daughter nucleus in an excited state. 
This energy is usually removed by a process that is the nuclear equivalent of 
the Frank-Cordon effect, called gamma emission. 
Since they are not particles but photons (even if very hard ones, with an 
energy that ranges from some KeV to a couple of MeV), they can travel 
trough matter until they not interact with some nucleus or electron that 
adsorb them. For this reason they are never completely halted but just 
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exponentially attenuated by interaction with matter. This characteristic 
makes them useful for radiodiagnostic applications. For detection sensibility, 
radioprotection and tissue self-absorption reasons the energy range of this 
radiation must be comprised between 100 and 600 KeV. 
1.3.4 Selection of the Radionuclide  
From the consideration of the previous paragraphs come out that the ideal 
radionuclide to be used in immunotherapy drug aimed at therapeutic purposes 
must be an alpha or a beta emitter with half-life in the range between some days 
and a couple of weeks. In the following tables we can see the candidate β and α 
emitters. 
Tab. 1.2: β emitter radionuclide of medical interest half-life ordered. 
Nuclide Half-life 
[days] 
Energy of the β 
emission [KeV] 
Energy of the 
strongest 
γ emission [KeV] 
127Tl 0.39 700  
188Rn 0.70 2130 155 
142Pr 0.80 2160 1600 
105Rh 1.48 740 320 
77As 1.62 680 239 
153Sm 1.95 800 1030 
149Pm 2.21 1070 289 
67Cu 2.58 540 185 
90Y 2.67 2280  
198Au 2.70 470 911 
186Rn 3.77 1080 131 
111Ag 7.47 1050 340 
131J 8.01 600 364 
The first (and until some years ago the only) radioisotope to be used for 
therapeutic aims was 131J. It has a good specific activity, appropriate half-life 
and is relatively cheap. As an halogen it can be easily inserted into organic 
compounds. Its Achilles’ heel are de-halogenation reactions, that causes 
dispersion of radioactive iodine trough the body with consequent irradiation of 
heal tissues. For this reason it would be sensible to replace iodine with other 
radionuclide (90Y, which present no γ emission and has a shorter half-life would 
be the best choice) and suitable BCA for this aim are under investigation. Since 
some Targeted Beta Immunotherapeutic drugs relying on BCA are in phase III 
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clinical investigation or already commercialized (Zevalin, developed by San 
Diego-based IDEC Pharmaceuticals and Schering AG, uses 90Y bounded to an 
Ig specific for an antigen called CD20 on the surfaces of B lymphocytes, cells 
that grow uncontrollably in non-Hodgkin's lymphoma) it was scientifically more 
interesting to focus onto alphaimmunotherapy. 
Of the potential candidates in the following table only the possible use of 
211At and 212Bi has been already enquired by other groups. This thesis deal with 
the possible use of 225Ac: the absence of collateral emissions in its decay process 
and the half-live of 10 days make it in fact an ideal candidate for radio 
immunotherapic applications. 
Tab. 1.3: α emitter radionuclide of medical interest half-life ordered. 
 
1.4  The Chelating Agent 
The core of this thesis, as organic chemist, is the identification and synthesis of 
suitable Chelating Agents. 
First trials of TAT (Targeted α-immunotherapy) drugsvii used commercially 
available CA, with the sacrifice of one CA donor functional group to form the 
covalent bond with the antibody. Nowadays two different approaches are 
worldwide followed on the choice of CA for Targeted Immunotherapy: the first 
can be ascribed to the Australian group of B. J. Allen at the St. Jorge Hospital in 
Sydneyviii, the second to the American company Actinium Pharmaceuticals of 
M. W. Brechbielix. 
• The Australian group deems that supplies problems of molecules 
synthesized at university laboratories overcome the advantages of higher 
stability constants of the Actinium-Chelating Agent complex and of lesser 
Nuclide 
Half-life 
[hours] 
Energy of the 
α emission 
[MeV] 
Mode of the 
strongest 
cascade 
emission 
Energy of the 
strongest cascade 
emission [KeV] 
213Bi 0.77 6 β 444  
212Bi 1.01 6 β 492 
149Tb 4.00 4 γ 43 
211At 7.20 6 β 80 
225At 240 6   
223Ra 272 6 γ 80 
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interference with the Ig quaternary structure. This row of priorities leads 
them to optimize the use of commercially available CA, mainly Open-chain 
CA, in clinical trials. 
• The American group on the contrary judge that a higher distortion of the 
antibody structure and mainly the effects of released Ac in the haematic flux 
can not be ignored. As consequence they have started a row of 
collaborations with universities and research center for the syntheses of 
tailored molecules that lead inter alia to the syntheses of Macrocyclic CA. 
In both approaches first step is donor atom identification, and then the 
structural frame that allows an optimal spatial arrangement of these donor atoms 
around the metallic ion is enquired. 
It must always be clear that since the final drug must be used in haematic 
environment the absolute thermodynamic stability is not the parameter that must 
be maximized: more important is the whole in vivo stability constant.  In fact, 
even if as rule of thumb the higher the thermodynamic constant (at pH = 4.7 and 
around 37 °C) the higher the in vivo stability, the in vivo constant considers also 
transmetallation1† and transchelation2† phenomena, of paramount importance in 
an environment with an high concentration of metallic ions (consider for 
instance Ca++ -present in haematic environment with a concentration of around 
2.5 mmol/dm3) and of several different species that show chelating properties 
(like serines and albumins). 
1.4.1  The Donor Atom 
Two different parameters have been taken in account to identified the best suited 
candidate atom: basicity and electronic density. 
• Basicity: An electronic lone pair must be provided by the donor atom to the 
metal ion to form a complex. As first approximation it can be tough that the 
more the basicity of the donor atom the higher the stability of the complex. 
From this point of view aminic groups should be better chelating agents then 
ethers or carboxylic groups.  
Since the substitution of one proton with an alkyl chain in amino groups 
increase its basicity (because of the electron-donating character of the alkyl 
group), it should be expected that the more the substitution around the N 
                                                     
1† When an atomic ion in the solution displace the metal in the complex. 
2† When a chelating agent snatches the metal ion from another one. 
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atom the higher its basicity and the stronger the complexation affinity 
toward cations. However the pKa values do not increase in a regular way 
with increasing alkyl substitution. In fact, tertiary amines are typically less 
basic than secondary systems. Solvation is responsible for this observation: 
increasing the number of alkyl groups on the amine nitrogen increase the 
unfavorable steric disruption of the solvent stabilizing shell of the conjugate 
acid. 
 
H
N
H
H
H H
N
H
H
Me Me
N
H
H
Me Me
N
Me
H
Me
pKa = 9.24 pKa = 10.62 pKa = 10.73 pKa = 9.79  
Scheme 1.1: pKa values of a Series of Simple Ammonium Ions. 
It can be ascribed to this effect the increase in stability of amino complexes 
in the series ammonia < tertiary < primary < secondary. So far a secondary 
aminic functionality seems to be the best candidate to design Chelating 
Agents. 
• Soft-Hard interactions: The basicity of the donor atom and consequently 
its attitude to share its lone pair with the metal ion influences only at first 
approximation the  stability constant of the complex. Even more important 
are a good superimposition between the ligand orbital containing the lone 
pair and the empty orbital of the metal cation and an equal charge density of 
the two orbital. These considerations are the base of Pearson’s theory of hard 
and soft interactions, that can explain, inter alia, why oxygen (an harder 
atom with Pauli electro negativity of 3.5) builds better complexes with 
alkaline metals, Ln and An while nitrogen (a softer atom with Pauli 
electronegativity of just 3.0) builds better complexes with transition and 
post-transition metals. 
In this optic the hard nature of Ac+++ ions must be taken in account: it is the 
first member of the post transition series where 5f atomic orbital are 
progressively filled up and that is named actinides after him. The valence 
electrons of the elements of this series and of the corresponding ions are, like the 
electron of the Ln series, quite insensitive toward their chemical environment, it 
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is to say they are hard and form ionic bonds. For this reason negatively charged 
anions and oxygen are more suited to build stable complexes with it than 
nitrogen. The ideal candidates turn out to be oxygen containing ones, such as 
carboxylic group, phosphonic acids or hydroxylamine. 
1.4.2: The Chelating Structure 
All An are big atoms that form bulky ions with a radio, determined on the basis 
of the distance ligand-atom/metal in a series of isostructural compoundsx, in the 
range 9-12 nm. Ac in particular, as the first member of its series and for the well 
known horizontal properties of the periodic table, is the biggest one. For this 
reason the most favorable coordination indexes are in 6-9 range and stable 
complexes formation requires the presence on the Chelating Agent of at least 6 
donor atoms. 
• Open-chain Chelating Agents: Historically first attempts to identify 
compounds with good chelating properties for Ac have been performed with 
commercially available nitrogen heteroaromatic compounds, such as 1, 10-
ortophenantroline (Ophen); 2,2’-bipyridine (Bipy) and 2,4,6-tris(2’-
pyridine)-1,3,5-triazine (TPTZ), scheme 1.2. 
• 
N N N N
1,10-phenanthrolinebipyridine
N
N
N
N
N
N
2,4,6-tri(pyridin-2-yl)-1,3,5-triazine  
Scheme 1.2: Nitrogen Chelating Agents studied for radio immunotherapeutic 
applications. 
These molecules are good chelating agents for An and the soft qualities of 
nitrogen lone pairs are used in nuclear facilities for separation operation of the 
  27 
 
hard An ions from the harder Ln ions. Nonetheless their stability constants are 
not big enough to foresee their use as chelating agents in drugs. To enhance their 
stability constant values harder donor atoms, i.e. Oxygen, must be present in the 
molecule. 
Experiments have 
then been performed 
with commercially 
available chelating 
agents containing 
carboxylic group xi 
(EDTA, perhaps the 
most ubiquitous used 
chelating agent, and its 
superior homologues, 
DTPA and TTHA), 
phosphonic acids 
(EDTMP, used in spent 
nuclear fuel reprocessing 
plants xii ) or 
hydroxylamine (THA), 
Fig. 1.5 and 1.6.  
Fig. 1.5: Oxygenated Chelating Agents 
N
NH2O3P
H2O3P
PO3H2
PO3H2
N
O
NHOH
O
NHOH
N
O
HOHN
O
HOHN
EDTMP
THA  
 
• Macrocyclic CA: As already said, some research groups were not satisfied 
of the stability constant of the former Open-chain CA (TTHA, the most 
stable, has a kf ≈ 1018) and prompted the synthesis of tailored CA, using the 
Macrocyclic Effect that was identified in the fifty years of last century. 
When e.g. in an ammonia complex two ammonia ligands are replaced by 
two methylamine molecules, its stability increases as expected as 
consequence of the higher basicity of amino groups. When two ammonia 
molecules are replaced by one molecule of 1,2-diaminoethane the stability 
increases even more. Two effects are responsible: 
• A geometric conformation that keep the second nitrogen atom near the 
metallic cation once that the first nitrogen has coordinated the metal 
• A geometric rigidity that keeps the two nitrogen atoms apart, minimizing 
their interactions and mutual repulsion. 
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The influence of these factors does not stop at the first substitution of 
ammonia atoms with more organized structures, but becomes more relevant 
with more complexes structures. 
 
N
NHOOC
HOOC
COOH
COOH
EDTA
N
HOOC
HOOC
DTPA
N
N
COOH
HOOC
COOH
N
HOOC
HOOC N
N
HOOC
COOH
N
COOH
COOH
TTHA  
Fig. 1.6: Carboxyl Chelating Agents 
 
To exploit this effect innumerable CA for charged species have been 
synthesized, from the two-dimensional crown ethers, to scorpionates (that use a 
tail that springs from the ion-molecule plane and form a bond with the metal ion 
from a direction incident to that plane) and to the cage molecules that surround 
and kidnap the ion like a prisoner in a jail. Among these possible structures 
Brechbielxiii and Ouadyxiv decided to synthesize a cyclic polyaza structure with 
carboxylic tentacles, the 1,4,7,10,13,16-exaazacyclooctadecane-1,4,7,10,13,16-
hexaacetate (HEHA, Fig. 1.7).  
They claim that this structure have the right mix between soft (nitrogen) and 
hard (oxygen) atoms needed to bind firmly Ac+++ ions without prompting 
transmetallation effect with the haematic Ca++. As explain in chapter 3 this work 
do not agree with this point of view: probably nitrogen atoms do not play a 
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central role in directly chelating the Ac+++  ion but are necessary to give to the 
tentacles the required configurational flexibility by the inversion process. 
 
N
N
NN
N
N
CH2CO2HHO2CH2C
CH2CO2H
CH2CO2HHO2CH2C
HO2CH2C
 
Fig. 1.7: HEHA, Macrocyclic CA 
Of the several geometric parameters that can be tuned in polyheterocyclic 
molecules, the dimension of the prong between two heteroatoms has been 
particularly studied. 
• Dendrimeric CA: One of the problems left open from the two previous 
class of molecules is the dose load. Each BCA can bear just one Ac+++ ion. 
Unfortunately, as can be seen in tab. 1.4, this leads to the death of the tumor 
cell just in the 70% of the sample population. To overcome this problem two 
ways, both unsatisfactory, are covered. The first one consists of increasing 
the number of BCA for antibody, but this often interfere with its quaternary 
structure and impairs its ability in recognizing the marker on the tumor cell. 
The second method is to increase the quantity of Ig-BCA given to the 
patient, but in this way the number of drug molecules that do not target the 
malignance increases and a higher dangerous dose harms health organs, 
mainly kidneys.  
o Tab. 01.4: Compared alpha and beta emitter efficiency. 
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The solution proposed in the chapter 4 of this thesis is the synthesis of 
dendrimeric CA, whose number of chelating tentacles change in accordance 
with the generation of the dendrimer and can be easily modulated with the 
exigencies of the drug to bind one or more Ac+++ ion. 
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Chapter 2 
 
PT-HEHA: Macrocyclic Pendant-Type BCA 
 
2.1 Structure 
As stated in the previous chapter one of the most promising molecule that 
encompasses the characteristic required to act as good BCA toward Ac+++ is the 
1,4,7,10,13,16-exaazacyclooctadecane-1,4,7,10,13,16-hexaacetate-2-p-
benzylisotiocianate (HEHA-NCS, 1). The PhD work of Dr. Ouadi1 demonstrated 
that the non bifunctionalized 1,4,7,10,13,16-exaazacyclooctadecane-
1,4,7,10,13,16-hexaacetate (HEHA, 2) has indeed the foreseen good chelating 
properties toward Ac+++, this encourages to make the hypothesis that also 
HEHA-NCS has akin chelating properties. 
These cage molecules are composed by a polyaza ring moiety containing 6 
nitrogen atoms, each with his lone pair available for interaction with the Ac+++ 
ion, and 6 acetic tentacles, each with its own carboxylic group, able to give 
their contribute in binding the metallic ion. The aromatic group in the pendant 
moiety gives both rigidity (a rigid pendant can keep the chelating moiety apart 
from the antibody minimizing the distortion of its quaternary structure) and it 
can provide an useful chromophore for analytical purposes. The covalent bond 
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with the Ig is provided by the good electrophilic isothiocyanate group, whose 
C=N double bond, with help of the thiocarboxylic moiety of the molecule, gives 
easily addition reaction with polarized molecules X-H, such as alcohols, acids 
and primary amines (Scheme 2.1). This group can also be used to bind the BCA 
to other supports, like polymers, to produce for instance chromatographic 
columns to explore a possible use of HEHA and of M-PT-BCA in general in An 
separations procedures. 
 
Scheme 2.1: Linkage of a BCA to a substrate. 
Alike to other chelating agents, also for HEHA-NCS its conformational 
equilibrium plays a crucial role: its lone pair and respective molecular orbital 
must be in the right spatial arrangement to overlap with the empty acidic 
acceptor orbitals of metal cations. Also the interaction of Ig and pendant 
moiety on the CA must be enquired. It is in fact possible that as BCA generates 
interference with Ig quaternary structure that can weaken its selectivity toward 
the specific antigen, so the effects of pendant and Ig on the CA could prejudice 
its chelating ability. 
Conformational analyses performed with CAMM (Computer Assisted 
Molecular Modeling) techniques, based on energy minimization with MM+ 
model, show a different dislocation of electron lone pairs in HEHA, HEHA-NCS 
and in HEHA-NCS-Polymer: 
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• HEHA has three carboxylic groups, available to bind the metallic ion, on 
each side of its ring, Fig. 2.1, and its cage has adequate size to allocate a 
Ln atom 
 
Fig. 2.1: Spatial disposition of carboxylic acid groups around the polyaza ring (left) and 
molecular cage (right). Color attribution: Blue nitrogen, Red oxygen, Gray carbon, White 
hydrogen, Pink lone pairs. 
• HEHA-NCS has the pendant benzyl-isothiocyanate that introduces an 
element of dissymmetry in the molecule. The pendant completely alters 
the conformational structure and the 6 carboxylic tentacles are 
asymmetrically divided between the 2 faces of the molecular ring: 4 of 
them are on one face and just 2 remain on the opposite one, Fig. 2.2.  
While the face with 4 tentacles can easily catch an Ac+++ ion, the 2 groups 
on the other one could not exert enough strong interaction to firmly bind 
the metal ion. 
 
• HEHA-NCS-Polymer, of interest for separation applications in column 
and that act as a model for BCA-Ig interactions, shows the same spatial 
distribution of carboxylic tentacles of the non functionalized HEHA, Fig. 
2.3. 
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Even if some group2 deems that the conformational structure of free HEHA-NCS 
impairs its employ in radioimmunotherapy applications, it must be kept in mind 
the dynamic nature of the binding process: the interaction between the 
charged ion and the BCA alters the conformational structure of the latter 
during the chelating process. 
  
Fig. 2.2: Spatial disposition of carboxylic acid groups around the polyaza ring in HEHA-NCS. 
Color attribution: Blu nitrogen, Red oxygen, Gray carbon, White hydrogen, Pink lone pairs. 
Each carboxylic tentacle of the CA flips rapidly about the nitrogen atom it is 
bond to, going trough a planar sp2 intermediate, with the well known inversion 
phenomenon of amines. If this phenomenon were hindered enantiomers were 
present and it could also be possible to identify and separate them. The 
experimental consideration that it does not happen supports our assumption. 
In a dynamic process, once that a couple of tentacles begins to interact with 
the cation the whole conformational structure of the CA changes, the flipping 
tentacles spend the biggest part of their time on the side of the molecule 
where the cation is, attracted by its positive charge, and all 6 carboxylic groups 
contribute to form the complex. It must not be forgotten that when all the 
carboxylic groups are on the same side of the molecule, all the nitrogen lone 
pairs point on the opposite side, straight away from the metallic ion. From this 
point of view the role of nitrogen atoms into the polyaza ring is not, as Ouadi 
and Brechbiel assert, to participate directly in binding the An cation and to give 
it the right mix of hard and soft ligands required to bind An, but just to give to 
the structure the necessary conformational flexibility. 
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These analyses and considerations support the choice of HEHA-NCS as useful 
BCA in radioimmunotherapy studies. 
 
 
 
 
  
Fig. 2.3: Spatial disposition of carboxylic acids around the polyaza ring in HEHA-NCS-Polymer. Color  
attribution: Blu Nitrogen, Red Oxygen, Gray Carbon, White Hydrogen, Pink lone pairs. 
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2.2 Total Ring Syntheses: 5+1 Approach 
Even if some syntheses of functionalized HEHA are known, a gram scale 
preparation procedure of the product, indispensable to proceed to a better 
characterization of the drug and to the subsequent clinical trials phases, has 
not still been set up. 
 
 
 Scheme 2.2: 5+1 synthesis of HEHA-NCS, steps 4-8. 1: MeOH/HClg, 100%; 2 
:Net3/BrCH2CO2Me/THF, 90%; 3: NaOMe/TMPA/MeOH/reflux, 50%; 4: BH3/THF, 55%; 5: 
Na2CO3/BrCH2CO2But/DMF, 82%; 6: SnCl2/EtOH, 62%; 7: TFA, 90%; 8: CSCl2, 90%
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The procedure with the highest yield, proposed by Ouadi, can be seen in 
Scheme 2.2. As usual in macrocycles syntheses the critical step is the ring 
formation. In this case to close the polyazaaminic ring a double condensation 
between a fragment containing 5 nitrogen atoms and a fragment with just one 
nitrogen atom is proposed (Step 3 in Scheme 2.2). Because of the size of the 
two fragments involved in this cyclization reaction the whole approach is 
named 5+1. Even if some of its steps have an acceptable yield, the alleged yield 
of the whole sequence starting from the precursor is just of 7% and the 
characterization of the final product is not complete. In fact in the reported 
paper3 only 100 mg of the final product are obtained and its only 
characterization is represented by a mass spectrometry analysis where the sole 
molecular peak is reported. 
 
Scrutinizing the former scheme it is possible to note that reaction steps 4-8 
appear trivial and cannot be optimized on the basis of the literature, while the 
first three steps are crucial and could be modified. In detail starting from (R,S) 
2-amino-3-(4’-nitrophenyl) propanoic acid (commercially available, albeit quite 
expensive) the synthetic strategy goes through the protection of the carboxylic 
acid groups as ester, employs the amino group as basis for the insertion of a 
carbomethoxymethyl substituent and allows the obtained methyl 2-
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Scheme 2.3: 5+1 synthesis of HEHA-NCS, steps 1-4. 1: MeOH/HClg, 100%; 2: NEt3/BrCH2CO2Me/THF,
90%; 3: NaOMe/TMPA/MeOH/riflusso, 50%; 4: BH3/THF, 55%; 5: Na2CO3/BrCH2CO2t-Bu/DMF, 82%; 6:
SnCl2/EtOH, 62%; 7: TFA, 90%; 8: CSCl2, 90%. 
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((methoxycarbonyl)methylamino)-3-(4’-nitrophenyl)propanoate (3) to react 
with 1,11-diamino-3,6,9-triazaundecane to obtain the cyclic diamide 3-(4’-
nitrobenzyl)-2,6-dioxo-1,4,7,10,13,16-hexaazacyclooctadecane 4. This amide, 
after reduction with NaBH4•THF, should give the key intermediate 2-p-
nitrobenzyl-1,4,7,10,13,16-hexaazacyclooctadecane (5), which with subsequent 
transformation (Scheme 2.3) would have given the target molecule 1. 
To achieve a gram scale synthesis it was necessary to improve the 
experimental procedures described in the previous Scheme to enhance the 
overall yield. 
2.2.1 Synthesis of methyl 2-amino-3-(4’-nitrophenyl)propanoate 
The first step, that in literature was performed with gaseous hydrogen chloride 
and anhydrous Methanol was drastically modified. The production of gaseous 
hydrogen chloride adding oleum to a solution of hydrochloric acid 37%, and 
subsequently bubbling the obtained wet gaseous hydrogen chloride through 
several stripping bottles in the effort to make it anhydrous, is not viable for 
gram scale syntheses. This reaction is replaced with a transacetalisation 
(Scheme 2.4) with 2,2-dimethoxypropane in anhydrous THF using p-
toluenesulfonic acid as catalyst. 
 
Scheme 2.4: Synthesis of methyl 2-amino-3-(4’-nitrophenyl)propanoate 
This reaction has been improved after similar reactions described in 
literature.4 Reaction driving force is represented by the higher thermodynamic 
stability of the products: acetone is more stable than its precursor 2,2-
dimethoxypropane) and it is not necessary to force the equilibrium by 
removing one product or using great quantities of expensive reactant. 
The second strong point of this reaction is to be absolutely anhydrous, 
being water used neither during the reaction nor during the product work-up. 
The excellent solubility of amino acids in water, due to their zwitterionic 
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characteristics,  would make extremely difficult the recover of not reacted (R,S) 
2-amino-3-(4’-nitrophenyl) propanoic acid from the reaction vessel. The by-
products of this new reaction, anhydrous methanol and acetone, can be easily 
removed at reduced pressure at the end of the reaction, leaving a 
chromatographically pure product that requires no further work-up. 
In the old synthesis two steps were required to achieve the same product, 
leading to inevitable decrease in yield. It was in fact necessary to neutralize the 
amino ester salt obtained in the first step during the reaction with gaseous 
hydrogen chloride with a basic solution of triethylamine. The new reaction 
gives the product with a chemical purity > 99% in few minutes, to be compared 
with the long reaction time of the old methodology reported in literature. 
2.2.2 Synthesis of methyl 2-((methoxycarbonyl)methylamino)-3-(4’-
 nitrophenyl)propanoate 
Since the previous reaction affords directly the free amine it can react without 
any preparation or deblocking step with methyl 2-bromoacetate (Scheme 2.5). 
 
Scheme 2.5: Synthesis of methyl 2-((methoxycarbonyl)methylamino)-3-(4’nitrophenyl)propanoate 
This step, performed in anhydrous THF, gives the product, after filtration and 
evaporation of the solvents under reduced pressure, almost quantitatively, to 
be compared with the 80% yield of Ouadi’s method. 
2.2.3 Synthesis of 3-(4’-nitrobenzyl)-2,6-dioxo-1,4,7,10,13,16-
 hexaazacyclooctadecane 
In the third step of the reaction sequence reported in literature, sodium 
methoxyde was prepared in situ in a THF solution. To this solution were added 
sequentially the compound 3 and 1,11-diamino-3,6,9-triazaundecane dissolved 
in methanol (Scheme 2.6). 
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Scheme 2.6: Synthesis of 3-(4’-nitrobenzyl)-2,6-dioxo-1,4,7,10,13,16-hexaazacyclooctadecane 
Also in this case the procedure has been modified: commercially available 
sodium methoxyde is dissolved in THF and the anhydrous tetrahydrofurane 
solution of 1,11-diamino-3,6,9-triazaundecane is added. After one hour at 
reflux the product 3 is added and the reaction proceeds for 96 hours. Another 
experimental improvement has been made in the purification procedures: The 
crude product is firstly  washed with water to eliminate the triethylamine and 
then purified by flash chromatography (acetone/pentane 20:80 v/v). 
Unfortunately the reaction yield is just 20%, in accordance with the yield 
reported by all other groups5,6 but the French ones, which claims a 50% yield.  
2.3 Total Ring Syntheses:  3+3 Approach 
This procedure (Scheme 2.7) is also named after the fragments that take part 
to the cyclization step, both containing 3 nitrogen atoms. The original sequence 
plans the conversion of the methyl ester of (R,S) 2-amino-3-(4’-
nitrophenyl)propanoic acid in the amide 6, that after reduction to amine 7 is 
protected7 and activated through the formation of tosylate 8. The sodium salt 
of this specie is finally cyclised with the tri-tosylated amine 11 to give the cyclic 
compound 12, an immediate precursor of HEHA. Also in this case the yield of 
this cyclization step is just around 20%. 
The first two steps of this reaction have till now been optimized: 
1) The esterification is performed like in Scheme 2.4 (quantitative yield) 
2) General conditions of the second step have not been changed, but of the 
work-up optimization leads also in this case to quantitative yield 
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Scheme 2.7: 3+3 synthesis of HEHA-NCS. 1: CH3OH/HCl, 88%: (2,2-dimethoxypropane/p-
toluenesulfonic acid, 100%); 2: CH3OH/NH2C2H4NH2, 90% (100%), 3: THF/BH3, 80%; 4: 
NaOH/pTsCl/H2O/Et2O, 70%; 1’) NaOH/pTsCl/H2O/Et2O, 82%; 2’) KOH/Etilen carbonate, No yield 
reported; 3’) MesCl, 80%; 5: NaH/THF, No yield reported. Yields and condition in brackets are 
referred to this thesis work. 
The way to set-up a gram-scale synthesis of HEHA by optimization and tuning 
of all the steps of the syntheses proposed in literature (Schemes 2.3 and 2.7) is 
still long, but from the results so far achieved other important upgrades of the 
processes can be foreseen. 
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Chapter 3 
 
New Approach to M-PT-BCA 
Synthesis 
 
Total cycle syntheses can be easily performed with 5, 6 or 7 member rings but 
ring closure becomes more and more difficult at ring size increasing. In this step 
collateral intermolecular polymerization reactions take place, along with the 
desired intramolecular condensation. Linear dimers and oligomers produced in 
these side reactions sink dramatically the yield of the cyclization step and of the 
whole procedure. 
 
Scheme 3.1: Condensation reaction. Path A: dimerization and polymerization byproducts. Path B: target molecule.  
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These two possible reaction courses are shown in Scheme 3.1 for HEHA-NCS 
synthesis. To minimize these side reactions it is necessary to work in high-
dilution conditions, with extremely precise reaction parameters whose 
identification is extremely time-consuming and expensive. 
To bypass this obstacle a brand new synthetic approach to PT-M-BCA, that 
could skip the cyclization step, was needed. This implied starting from the 
polyaza ring structure and converting it in a useful scaffold for the insertion of 
several kinds of pendant on the cycle, opening the way to the production of a 
broad range of new M-PT-BCA. It would then be possible, with an “ad hoc” 
experimental campaign, to chose among these molecules those with the best 
affinity for the metal ion and the antibody. The considerations expressed in 
former chapters made natural the choice of 1,4,7,10,13,16-
exaazacyclooctadecane (13), commercially known as hexacyclene (HEXA, Fig. 
3.1), as starting material. 
∗
NH
NH
HN
∗
∗
HN
∗ ∗
∗
NH
N
H
HN
HNNH
H
N
∗
∗
13 14  
Fig. 3.1: 1,4,7,10,13,16-exaazacyclooctadecane, commercially known as hexacyclene (13) 
 and 1,4,8,11-tetraazacyclotetradecane (14), commercially known as Cyclame 
With this approach the task became the introduction of the pendant (for the 
target molecule the 4-isothiocyanatobenzyl or a suitable precursor) trough the 
functionalization of only one endocyclic methylene group. Taking into account 
Hexacyclene high cost, the whole reaction sequence has been implemented 
employing 1,4,8,11-tetraazacyclotetradecane (14), commercially known with the 
name of Cyclame (Fig. 3.1). 
 This molecule, available in large amounts in these laboratories, is a smaller  
homologue of 13 containing the same functional groups. As consequence they 
should have the same reactivity and procedures set-up on Cyclame should 
behave similarly to hexacyclene. 
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3.1  Synthetic Strategy 
Possible strategies exploit the endocyclic nitrogens to introduce a functional 
group, which induces a positive or negative polarity on carbon atoms in α 
position (marked with a star in Fig. 3.1). The subsequent step is the reaction 
between the best-suited synthetic equivalent of this synton with a reverse 
polarity synthetic equivalent of the pendant. 
 
Scheme 3.2: Synthetic route to a cyclame M-PT-BCA using p-tosyl as protective group. 
 The first synthetic strategy was based on the protection of endocyclic 
nitrogen atoms, followed by reaction with a suitable strong base, in equimolar 
amount to the tetra-protected Cyclame, that should lead to the formation of an 
anionic specie through the removal of one α proton. It is clear that because of 
the high symmetry of the molecule all atoms in α position to the endocyclic 
functionalized Nitrogens are equivalent for our synthetic aims. The extraction of 
a second proton from the same molecule should have been prevented by the 
negative charge on the formed anion. The reaction of this anion with a positive 
synthon of the pendant would have given (Scheme 3.2) the functionalized cycle. 
Kinetic considerations suggest that reaction between the unreacted ion and the 
PT-MCA to give back the unreacted macrocycle and the [PT-MCA]- ion is not 
competitive. 
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3.2 Paratoluenesulfonyl as protective group 
Paratoluenesulfonyl group was chosen for its good protective features for amino 
groups1: it does not give side reactions with the n-butyl lithium, that has an 
hardness incompatible with the softness of the sulfonyl group,2 and can be easily 
cleaved through basic hydrolysis. 
3.2.1 Synthesis of 1,4,8,11-tetraparatoluenesulphonyl-1,4,8,11-
 tetraaza-cyclotetradecane 
In literature is reported3 an expensive and cumbersome synthesis of 1,4,8,11-
tetraparatoluenesulphonyl-1,4,8,11-tetraazacyclotetradecane (15). In this 
synthesis eight equivalents of paratoluenesulfonyl chloride give a mixture (1:1) 
of tri- and tetratosyl cyclame. The final yield, after purification is only 35%. 
In this work a new synthetic procedure has been set-up, based on phase 
transfer catalysis concept. Cyclame and paratoluenesulfonyl chloride (1:4) react 
together in a double-phase medium (chloroform/aqueous solution of sodium 
hydroxide at 20%) using benzyl-trimethylamonium bromide (Triton B) as 
phase-transfer catalyst. This procedure does not make use of organometallic 
reagents and can be performed without the employ of anhydrous solvents and 
inert atmosphere. After 12 hours 15 was recovered almost quantitatively. 
3.2.2 Synthesis of 4-nitrobenzyl bromide 
The synthesis of 4-nitrobenzyl bromide, immediate precursor of 4-
isothiocianate benzyl moiety, was easily carried out according to two different 
methodologies (Scheme 3.3): 
 
Scheme 3.3: Systhetic strategies used for 1-bromomethyl-4-nitrobenzene preparation. 
 CH2Br
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Nitration in para position of benzyl bromide performed with fuming nitric acid 
(98%) in presence of Amberlist 15-H, a sulfonic acid resin, as catalyst.4 
Unfortunately this technique produced para and ortho isomers in a 2:1 mixture 
isolated by flash chromatography5 
• Radical bromination of a benzyl Hydrogen of paranitrotoluene has 
been developed to avoid the separation step trough the reaction of 
paranitrotoluene with N-bromosuccinimide (NBS) in carbon 
tetrachloride. The solution, gauged by GC, was refluxed till no more 
precursor was present, by means of a procedure described for 
analogous substrates.6 The subsequent recrystallization of the reaction 
crude product gave the chemically pure 1-bromomethyl-4-
nitrobenzene in a 75% yield. 
3.2.3 Functionalization of the cycle 
This step went through the reaction of 15 with an equivalent of n-Butyl Lithium 
and, after formation of intermediate 16, with one equivalent of 1-bromomethyl-
4-nitrobenzene. Unfortunately it did not give 2-(4’-nitrobenzyl)-1,4,8,11-
tetraparatoluenesulfonyl-1,4,8,11-tetraazacyclotetradecane (17), but 15 was 
quantitatively recovered from the reaction mixture. 
3.3 Nitroso as protective/activating group 
The lack of reactivity of 15 can be ascribed to an insufficient acidity of the 
Hydrogen atoms in α position to the endocyclic sulfonamide groups. It was thus 
necessary to substitute the tosyl group with something that could not just protect 
the amino functionality, but also enhance the Hydrogen acidity. The ideal 
candidate was the nitroso group7 whose reactivity has been widely studied by 
Seebach8 and was quite well known. There were two possible approaches: 
• Nitrosation of only one amino group, trough the protection of all the 
other endocyclic nitrogen atoms9, facing the consequent separation of 
products with none, one or several nitroso groups at this early stage 
• Total nitrosation of the substrate, that implies separation between mono 
and poly pendants chelating agents at a later synthetic stage. 
The latter strategy (Scheme 3.4) was chosen because it allows a synergic 
approach, nowadays so widely recommended in industrial management 
manuals.  
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Scheme 3.4: Synthetic route to a cyclame M-PT-BCA using NO as protective/activating group. 
Cyclic nitrosamines can in fact not only be used as synthetic scaffold for the 
synthesis of a wide range of PT-MBCA, but their complexing properties toward 
transition metals and Ln are well known10. It is of scientific and applicative 
interest to study, with new suitable CA, if they form stable complexes also with 
It must be kept in mind that even this work deems that nitrogen atoms in 
HEHA have just a structural function and do not give an appreciable 
contribution to the Ac+++ binding, Ouadi and Brechbiel 11  have the opposite 
theory: a right balance between hard oxygen atoms and soft nitrogen atom in the 
same molecule is required to build a good CA for An. Such a balance could be 
achieved with help of nitroso group. In same N-nitroso complexes in fact both 
oxygen and nitrogen participate to the complex formation binding the metallic 
cation.12 
In addition the cyclic polynitroso compounds produced as intermediates in 
this synthetic path can be interconverted by reduction in cyclic polyhydrazines,  
whose chelating properties towards An are also of interest. 
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3.3.1 N-nitrosamine structure 
Nitrosamine are represented by two main resonance structures the second one 
representing the commonly used 1,3 zwitterionic form with a diazenic double 
bond, Fig. 3.2.  
 
Fig. 3.2: Main N-nitrosamine resonance structures. 
As a consequence of the relatively high weight of this limit resonance 
structure, the free rotation around the N=N bond is somehow hindered.13 The 
presence of this partial double-bond characteristics implies the existence of 
isomerism: E-Z when the simple diazenic bond is considered, syn-anti around 
the ring structure when a cycle is present. An accurate determination of the 
relative weigh of this two limit structures, for a better understanding and 
foreseeing of the reactivity of this class of compounds and of the single 
nitrosamines, is a field that involved researchers for many years. It must be kept 
in mind that since the rotational barrier is just around 20 Kcal/mol,14 compared 
with the 60 Kcal/mol of a C=C double bond, it is not always correct to speak of 
stereoisomerism and for compounds with low N-N rotational barrier the 
denomination conformer is more appropriate. It is also reported15 a link between 
the stability of nitroso compounds and their rigidity: products that undergo easy 
N-NO bond cleavage have little diazenic character and as consequence can 
rotate more easily around the N-NO bond and exist just as conformers.  
 
Fig. 3.3: E-Z isomerism in a N-nitrosamine. R has a higher Cahn-Ingold-Prelog priority group then CH3. 
NMR is the methodology of election for configurational assignment of 
nitroso compounds, 16  with this technique it is possible to discriminate for 
example α-syn protons –whose resonant frequencies are at higher fields- from 
α-anti protons.17 Alike to alkenes stereoisomers, “cis” compounds are less stable 
than “trans” (Fig. 3.3) and the bulker the R group the higher the stability of 
“trans” stereoisomer.18  
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Tab. 3.1: 1,4,8,11-tetranitroso-1,4,8,11-tetraazacyclotetradecane production methodologies. 
Reaction Reagents Conditions Yield 
1 NaNO2/HCl 
in aqueous solution 
Controlled pH (5.5) with 
acetic acid, room 
temperature 
75% 
2 HNO2 gas 
from NaNO2 and oleum 
Bubbling gas at -5°C 70% 
3 SiO2/H2O/NaNO2/Nafion-H 
in heterogeneous catalysis 
Stirring at room 
temperature 
0 
4 TMSi-ONO 
from NaNO2 and 
(CH3)3SiCl 
Stirring at room 
temperature, THF as 
solvent 
90% 
Several procedures for the synthesis of these products, summarized in Table 
3.1, have been investigated. 
Leaving out some exotic reactions like radical19 ones (that use metallic ions 
and for this reason are not suited for this work aims)20 or hydrazines oxidation21 
(where the synthesis of the starting reagent would be more difficult of the 
synthesis of the product), all syntheses of nitrosamine employ the 
nucleophilicity of amino nitrogen, Fig. 3.4. 
 
Fig. 3.4: Synthesis of N-nitrosamine using amino nitrogen nucleophilicity. 
3.3.2 Synthesis at controlled pH  
From Tab. 3.1 arises clearly that Cyclame exhibits a more complex and peculiar 
reactivity in normal nitrosation conditions than standard aliphatic or alicyclic 
amines. 
It is extremely important, for instance, to keep the reaction medium at a 
controlled acidity during the reaction of Cyclame with sodium 
nitrite/hydrochloric acid in aqueous solution. It must be in fact avoided a 
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complete neutralization of aminic groups with an acid, that would drop nitrogen 
nucleophilicity, but the solution must be enough acid to allow the existence in 
appreciable quantities of the nitrosating cation [H2NO2]+. For this reason the 
reaction evolution had to be constantly gauged by a pH-meter and pH value 
must be kept in 5.0 – 6.0 range with carefully addiction of acetic acid (Table 3.1, 
reaction 1). The product, 1,4,8,11-tetranitroso-1,4,8,11-tetraazacyclotetradecane 
(18) was recovered after an easy filtration and a careful washing with cold 
water. 
Crystallographic and IR spectra of 18 synthesized with this methodology fit 
perfectly with literature data. In IR spectra N-H stretching bands (3000 cm-1) are 
absent, while it is possible to observe the classical double tipped N=O stretching 
band (1450 and 1428 cm-1), the N-N stretching (1139 cm-1) and the N-N=O 
bending (555 cm-1)1. 
2θ 
Fig. 3.5: Comparison  between 18 measured diffraction spectrum (black) and calculated one (red). 
Also the X-ray spectra, registered on a crystal of tiny dimensions, is super 
imposable to that reported in literature. In Fig. 3.5 it is possible to compare the 
first 60° of the X diffraction spectra of a polycrystalline sample of 18 prepared 
during this thesis (black spectrum) with the theoretical spectrum (red line) 
calculated for a single crystal of the same molecule starting from structural 
                                                     
1) These νNO bands are lover than those observed for C-nitroso compounds (1621-1539 cm-1), and this 
observation is usually used as evidence for the weakened N-O bond due to 1,3 zwitterionic resonance structure 
in fig. 3 (Rao, C.N.R; Bhaskar, K.R. “The Chemistry of the Nitro and Nitroso groups. Part I. Feuer, H., Ed 
Interscience, New York, 1969).  
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data.22 It is clear that is the same crystal phase of the same substance. Different 
intensity in same peaks is due to preferential orientation effects. 
A relevant discrepancy existed between the solubility data (Table 3.2): the 
product synthesized in this work is soluble only in boiling water and partially in 
dimethyl sulfoxide, while Sousa’s group claims that the product is also soluble 
in Acetone, dichloromethane and acetonitrile. 
Tab. 3.2: Comparison between solubility data found in this work and data reported in literature. 
Solvent Solubility in this work Solubility reported 
Water at reflux soluble 
Triethylamine Insoluble  
Chloroform “  
THF “  
DMF sparingly soluble  
Acetone Insoluble soluble 
Hexachlorobutadiene “  
Hexafluoroxylene “  
Benzene “  
Nitrobenzene decomposition at high 
temperature 
 
Acetonitrile “ soluble 
Hexametapol sparingly soluble  
DMSO “  
Dichloromethane Insoluble soluble 
 
To clarify this discrepancy the published procedure has been repeated. 
3.3.3 Synthesis with gaseous nitrous acid  
The procedure reported in literature for this nitrosation is very awkward and 
cumbersome: extremely carcinogenic gaseous nitrous acid, produced in situ by 
oleum addition to solid sodium nitrite, is bubbled trough a water solution of 
Cyclame. No yield is given in the related paper, and the characterization, lacking  
both 1H and 13C NMR spectra, is incomplete. 
Anyway the product obtained in this work had exactly the same IR spectrum 
and solubility properties of that obtained in the previous paragraph. 
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3.3.4 Synthesis via Amberlist 15 and wet silica  
To be sure that the synthesized product was correctly identified a cross 
reference, obtained through the synthesis of the same product with other well 
tested methodologies, was necessary. This necessity was also an opportunity to 
find reactions with higher yields. The use of several acids, both protic23 and of 
Lewis,24 have been considered, along with the use of halogen ions.25 
One of these alternative methodologies, applied with mono and diamines, 
both aliphatic and alicyclic, seemed really promising for its simplicity (Table 
3.1, reaction 3). Wet silica,26 modified by means of nitrous acid, prepared in situ 
using Amberlist 1527 or Nafion-H®28 as proton source, is used as heterogeneous 
catalyst in a reaction where all reagents can be comfortably filtered away at 
reaction end. Disappointingly, when this procedure was applied to Cyclame no 
product recovery was possible, probably because of the strong interactions 
between the solid and the organic phase, that remained adsorbed on the silica. 
Several attempts have been performed to extract the product, but only with 
Acetonitrile was possible to recover a compound, namely 2-nitrosoacetonitrile, 
probably arising from the degradation of the product during the extraction with 
Soxhlet apparatus. 
3.3.5 Synthesis with silicon compounds  
Still in need of a cross reference 18 has been synthesized with an innovative 
nitrosation methodology that is currently generalized to other amino substrates 
in this laboratory. 
The starting point of this new strategy is the analysis of the experimental 
results of the nitrosation reaction carried out with the Zolfigol’s25 strategy in the 
previous paragraph. This reaction should proceed in two different steps: the 
formation of a nitroso silyloxyde that subsequently acts (Scheme 3.5) as 
nitrosating agent toward amino group. The thermodynamic stability of the 
syliloxyde ion leaving group produced at the reaction end should be the driving 
force of the whole reaction. Unluckily in the reaction with the Cyclame the 
interactions between the overwhelming number of Si-OH functionalities and the 
Nitrogen atoms in the reacting molecules became so strong that a recovery of 
the product becomes impossible. The problem can be faced employing an 1:1 
ratio between the nitrososyliloxyde and the amino group without the interference 
of Si-OH groups. 
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To test this idea trimethylnitrososilane has been synthesized for the first time 
in this laboratory by reaction of Chlorotrimethylsilane with Sodium nitrite in 
dichloromethane. The product of the subsequent reaction with cyclame, obtained 
in good yield (Table 3.1, reaction 4), has the same IR spectrum of the molecule 
produced with the first methodology (Table 3.1, reaction 1) or with the 
methodology reported in literature (Table 3.1, reaction 2). 
At this point it was interesting to verify the nitrosation properties of nitroso 
trimethylsilyloxyde. This interesting molecule should contain two different 
electrophilic sites: the hard silicon and the soft nitrogen atoms. Since amines are 
soft basis, it is sensible to think that the soft nitrogen lone pair can overlap the 
antibonding N=O orbital, prompting the elimination of  the good leaving group 
trimethylsilyloxyde  ion, as sketched in Scheme 3.5. 
 
Scheme 3.5: Synthesis of nitroso compounds using nitroso trimethylsilyloxyde.  
Also in this case the obtained product had the same solubility, IR and NMR 
spectra of the others obtained in the previous syntheses. 
3.3.6 Structure determination  
As already stated, the synthesis of 18 through so many procedures was 
necessary because of its insolubility in all more common and exotic solvents, 
that makes its complete characterization difficult.. 
 
Fig. 3.6: MS of 18 reported in literature performed by APCI-SIM. 
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It must also be recorded that published mass spectroscopy analysis results 
does not completely fit with the mass spectroscopy results obtained during this 
thesis. This discrepancy can be tracked down to the different instruments used to 
perform the analysis 
While Sousa’s group utilized a LCMS (Liquid Chromatography - Mass 
Spectrometry) with a mass spectrometer APCI-SIM (Atmospheric Pressure 
Chemical Ionization-Single Ionization Molecule) interfaced with a liquid 
chromatograph (isocratic elution performed with Acetonitrile/water = 80/20 in a 
Shimadzu column C18 1250 x 20 mm, 4.6 lm with a Shimadzu 2010 
equipment), in this work the sample was analyzed with a MALDI-TOF (Matrix 
Assisted Laser Desorption/Ionization-Time Of Flight) instrument. 
 
Fig. 3.7 a: MS of 18 obtained in this work with a MALDI-TOF. Mass range300-400. 
In reported data (Fig. 3.6) a higher molecular peak M++1 is detected (m/z = 
317), that in our data (Fig. 3.7 and Table 3.3) is present as a smaller peaks 
flanked by a twin M+-1 peak (m/z = 315). Along with these two peaks an 
heavier peak (m/z = 602) corresponding to a more complex dimer structure has 
been detected. Also peaks corresponding to M+-NO (m/z=288) and M+-2(NO) 
(m/z=257) are identified. 
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From this data and from the presence of others peaks heavier then the molecular 
peak of 18 it has been possible to identify a more complex dimer, whose 
structure and fragmentation path is shown in Table 3.3 and Scheme 3.6. 
 
Fig. 3.8 b: MS of 18 obtained in this work with a MALDI-TOF. Mass range 400-800. 
Even if some group deems29 that this dimer is produced during the synthesis, 
hypothesis that could explicate the different solubility of our product compared 
with the solubility of the product reported in literature, this work, considering 
the peaks relative highs is confident that some dimers are generated during the 
Mass Spectrometric analysis: in MALDI-TOF analysis condition dimers arise 
from a Chemical Impact (CI) process, between 18 and one of its stable radical 
produced during the ablation or ionization phase, as shown in Scheme 3.6. 
Tab. 3.3: MS fragmentation obtained in this work by MALDI-TOF 
 
  
 
m/z Signal Fragment m/z Signal Fragment 
602 60 [M-O+H]+2 315 26 [M-H]+ 
571 42 [M-NO]+2 301 30 [M-O+H]+ 
346 28 [M+2O-2H]+ 288 260 [M-NO]+ 
331 31 [M+O-H]+ 257 310 [M-(NO)2+H]+ 
317 26 [M+H]+ 196 90 [C9H18N5]+ 
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Scheme 3.6: Fragmentation path of 18 by MALDI-TOF MS. 
In this work is has also been possible to perform 1H NMR analysis of the 
sample in DMSO d6 at 80°C. In this spectrum (Fig. 3.8) it is possible to 
recognize four different isomers, that can be associated to the four different 
relative position of the N-NO groups as shown in Fig. 3.9. 
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Fig. 3.9: 1H NMR spectrum of 18, acquired in DMSO d6 at 80°C. 
That the product 18 had several isomers and not mere conformational 
structures was expected as it can be crystallized in boiling water and melts 
without decomposition, behaviors that attest an extremely high diazenic 
character and as consequence the existence of stable isomers. 
 
Fig. 3.10: Four possible stereoisomers of 18. Ellipse represent the ring plane and the studs symbolize NO groups. 
The third structure of Fig. 3.9 is sketched and simulated as example in Fig. 
3.10, with two vicinal nitrosoaminic groups over the ideal molecular plane and  
the other two under this molecular plane. 
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1H NMR spectrum for this isomer (Fig. 3.7), simulated by SPINIS software 
(version 1.94-Impact/m18122/cc558), shows clearly the multiplets for aliphatic 
methylenes (–CH2-CH2-CH2-) and a more complex situation for methylene 
groups in α position to N-nitroso groups. This simulation is in good accordance 
with the registered spectrum (Fig. 3.8) where the four signal groups correspond 
to the four identified isomers. 
 
Fig. 3.12: Simulation (SPINUS Software) of 1H NMR spectrum of the isomer of 18 reported in Fig. 3.11. 
It was not possible to perform analogues 13C NMR analyses because the 
product undergoes slow degradation processes and is scarcely soluble even in 
dimethyl sulfoxide, this means that it is neither possible to acquire data for a 
long period of time nor to perform analysis on very concentrate solutions. 
3.3.7 Cycle Functionalization 
Once that the structure of compound 18 had been proved, the following step was 
to exploit the well known acidity of proton in α position to N-NO group for the 
insertion of a suitable pendant. 
The first used base was n-butyl lithium. In a equimolecular reaction between 
18, dissolved in anhydrous THF at -20°C, and n-BuLi a red-brick solution was 
obtained. 30 
 
Fig. 3.11: Structure simulation of the third isomer in Fig.9. 
Color attribution: Blue nitrogen, Redo, Gray carbon, White hydrogen, Pink lone pairs  
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Unfortunately the addition of 4-nitrobenzyl bromide did not bring to the 
formation of the foreseen products but, thought a reaction between the strong 
base and 18, produced 1-nitrosobutane. 
Transnitrosation is a threat that lurks constantly in working with nitroso 
compounds, 31 that act as nitrosating agents32 at moderate temperature33 or with 
nucleophiles in acid solutions. For this reason we decided to try the use of a 
milder base as lithium diisopropylamide (LDA), the same base used by Seebach 
in his seminal experiments 34  with aliphatic and alicyclic mono and 
dinitrosamines. Unfortunately also this attempt did not bring the expected 
results, in open contrast with what reported in literature for similar compounds. 
The cause of this unexpected reactivity can be tracked down to the lack of 
solubility of this compound. Being trapped in a crystal it is not free to bend and 
rotate reaching the spatial conformation necessary to N-nitrosoaminic group to 
extract a proton placed on its α Carbon. 
 
Scheme 3.7: Resonance structures of 18. 
Acidity of these hydrogens in N-nitrosamines is correlated not only to 
resonance I ↔ II in Scheme 3.8, but more important is the zwitterionic 
equilibrium between structure II and III through a cyclic five-ring intermediate, 
where the proton must be in a syn-periplanar position respect  to the negatively 
charged oxygen atom. This equilibrium is normally shifted on the left side. Ab 
initio studies on the charge densities of the NNO moieties of Nauman and co-
workers,35 based on data obtained via photoelectron and electronic absorption 
spectra, are compatible with an electronegative oxygen atom, an electropositive 
nitroso N-atom and a slightly electronegative amine N-atom. They also 
proposed an involvement and redistribution of molecules’ σ electrons. From 
their calculation the HOMO of R2NNO is a non-bonding orbital (lone pair) 
localized mostly on the oxygen atom, with the second HOMO being the nitroso 
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π orbital. Also UV-visible data,36 that show absorption in the 340-385 nm 
(ε~100) and 235 nm (ε~7000) ranges that can be assigned to n → π* and to a π 
→ π* transition respectively, support the assumption of Nauman’s group. 
 
Scheme 3.8: Required stereoelectronic conditions for electrophilic functionalization. 
The existence of this zwitterionic species has been further demonstrated37 
with a suitable  electrophile, that saturated the negative charge on the oxygen 
atom annihilating  the acidity of the hydrogens on its α carbons. 
The conclusion is that the formation of the carbanion can occur only if the 
negative charge on the oxygen atom is in syn-periplanar position respect to the 
hydrogen that has to be removed. In this contest bases have not the function of 
directly remove the proton, but to shift the equilibrium within reaction III ? IV 
on the right side (Scheme 3.8). 
 
 
 
 
 
 
 
 
 
 
 
 
The key step is hardly influenced by the base nature or strength, but principally 
by relative spatial disposition of the involved groups38. Conformational analysis 
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Fig. 3.13: Structure simulation of N-nitroso oxygen atom in syn-periplanar position 
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nitrogen, Red oxygen, Gray carbon, White hydrogen, Pink lone pairs. 
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of zwitterion II (Fig. 3.12) shows that the cyclic structure of 18 (Scheme 3.8) 
hinders a suitable stereoelectronic arrangement of the involved atoms: the 
conversion of I in V is stereoelectronically forbidden. The reaction between 4-
nitro benzyl bromide and the carbanion of 18 does not occur because the latter 
cannot be synthesized. 
It is a remarkable coincidence that the peptidic synthesis of 1 attempted by Moi 
and Meares39 did not achieve the target product for analogous intermediates 
solubility problems. 
3.4 Umpolung of the Synthetic strategy 
Since the former strategy was not practicable a sensible alternative was the 
umpolung of the sinthons identified in the retrosynthetic analysis. 
It became necessary to identify a suitable Cyclame derivative with a formal 
or effective positive charge on the α carbon atom to the N-nitroso group that 
could react with a synthetic equivalent of the anion of 4-nitrotoluene.  A good 
candidate was for instance the 1,5,8,12-tetraazacyclotetradeca-1,4,8,11-tetraene 
(21, Scheme 3.9), along with all the other tetraenes that could be written 
considering the four double iminic bonds placed on one side or on the opposite 
side of each nitrogen atom. 
 
Scheme 3.9: Cycle functionalization via imine formation. 
The planned synthetic route went trough a reaction of cyclopolyimine 21 
with a suitable nucleophile to give compound 22 (or one of its equivalent with 
the pendant bounded to any other carbon in α position to one nitrogen atom). 
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This product after reduction (NaBH4, H2/Pd(C), LiAlH4) should give the 
functionalized Cyclame 23. 
3.4.1 Chlorine as protective/activating group 
There are not too much synthetic functional group interconversions to transform 
a secondary amine into an imine. An easy strategy goes trough the halogenation 
of the secondary amine followed by a formal hydrohalic acid elimination with a 
strong base. 
 
Scheme 3.10: Synthesis of 1,4,8,11-tetraazacyclo-1,4,8,11-tetrachlorotetradecane (24). 
In this thesis the Cyclame was chlorinated  in an aqueous solution with an 
excess of sodium hypochlorite,40 Scheme 3.10. The powder-pink precipitate, 
dried under vacuum condition at room temperature, gave with 90% yield 
1,4,8,11-tetraazacyclo-1,4,8,11-tetrachlorotetradecane (24). 
Errore. L'origine riferimento non è stata trovata. 
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3.4.2 Synthesis of 1,5,8,12-tetraazacyclotetradeca-1,4,8,11-tetraene. 
Several attempts to get the compound 21 in different reaction condition (Table 
3.4) gave only degradation products. Polyimine 21 (along with its E and Z 
isomers) is probably formed in reaction 6-8 of Table 3.4, but they are not stable 
in the used reaction conditions. Imines have in fact a strong tendency to give 
polymerization reactions. It is for instance known41 an oligomerization reaction 
of 2,3,4,5-tetrahydropyridine in similar conditions, Scheme 3.11. 
 
Scheme 3.11: Imine oligomerization. 
3.4.3 Potassium Superoxide as protective/activating group 
To overcome this problem potassium salts, that can perform the functional 
group interconversion from chloramines to imines under mild conditions,42 were 
used (Table 3.4, entries 1-5). This reaction goes trough the substitution of the 
Chlorine atom with a basic nucleophile and only in a second step, with an 
intramolecular mechanism (akin to the pyrolysis of aminic sulfonic esters, 
acetate or N-oxides) the double bond is produced. For example in Scheme 3.12 
is represented the foreseen reaction progress with potassium superoxide.43 
 
Scheme 3.12: First steps in synthesis of 21 with Potassium Superoxide. 
Since also in all these reactions there is an interaction between an N-bonded 
functional group and an hydrogen on the α carbon to the nitrogen atom, with the 
formation of an intermolecular cyclic intermediate, also in this case all involved 
atoms must be placed in one exact spatial position and fulfill stringent 
stereoelectronic prerequisites. Also in this case the study of molecular models 
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for the intermediate 25, as happened with the nitroso group, shows that the 
required conditions are not accomplished. For this reason, at best of my 
knowledge, it is not possible to use 1,4,8,11-tetrasubstituted-1,4,8,11-
tetraazacyclotetradecane as intermediate for the synthesis of functionalized 
polyazacycle. 
3.5 Cyclic Polyhydrazine CA 
As already said at the beginning of this chapter the nitroso group was chosen 
keeping in mind the possibility of its use as intermediate for the synthesis of 
cyclic polyhydrazine CA. 
 
 
Scheme 3.13: Synthesis of 1,4,8,11-tetraamino-1,4,8,11-tetraazacyclotetradecane. 
The FGI described in Scheme 3.13 can be performed in several ways,44 but the 
critical step is not the interconversion itself but the product isolation. Hydrazines 
have in fact a very strong affinity for water45  in acid, 46  basic47  and neutral 
solutions,48 and the reaction should be carried on neither in aqueous medium nor 
with production of water. 
For this reason the reduction has been performed in chloroform or benzene 
at reflux, with cyclohexene in hydrogen transfer conditions and Pd/(C) as 
catalyst. In this condition the reaction was hardly reproducible and gave 
different quantities of 1,4,8,11-tetraamino-1,4,8,11-tetraazacyclotetradecane 
(26) along with significant amounts of Cyclame as byproduct. The probable 
catalytic intermediate palladium hydride is able, due to its softness, to give 
demolition reaction of the soft N-N bond. 
To bypass this problem the reaction has been performed in milder condition 
(room temperature) using a titanium(III) chloride solution as catalyst. In this 
condition the reaction gave the expected product, but its extraction and recovery 
was extremely complicate even using ethyl acetate. 
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In conclusion, even if this experimental cycle did not open a new synthetic 
path to the production of PT-MBCA, a new chelating agent candidate, the 
1,4,8,11-tetraamino-1,4,8,11-tetraazacyclotetradecane, has been synthesized and 
new synthetic paths to 1,4,8,11-tetranitroso-1,4,8,11-tetraazacyclotetradecane 
have been set-up.  
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Chapter 4 
Synthesis of Dendrimeric 
Bi-functionalized Chelating Agents  
As stated in cap. 1 one of the open problem of Macrocyclic Pendant-Type BCA is 
their limited dose load. Each complex can bear only one Ac+++ ion, that only in 
70% case lead to cancer cell death. Both employed solutions (increase of the 
number of BCA for antibody and of the Ig-BCA given to the patient) have big 
drawbacks and are unsatisfactory. The number of tentacles in Dendrimeric 
Chelating Agents depends on the dendrimeric generation and can be easily set 
to bind more Ac ions. 
There was no article or hypothesis on the complexing properties of 
dendrimers toward An when this thesis began, but last March Mamadu Diallo 
made an oral report at the 233rd ACS National Meeting in Chicago1 on the 
binding properties of poly(amidoamine) and poly(propyleneimine) dendrimers 
toward U(IV). On one side this take us away the primogeniture of the idea, on 
the other one support the validity of studying this field. 
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4.1 Dendrimers: Highly-branched polymers 
4.1.1 Structure 
Highly-branched polymeric structures can be seen as the chemical equivalent 
of fractal geometry, where a very simple basic structure or operation is 
reiterated in a fixed algorithm to obtain complexes, and often esthetically 
beautiful, structures. Thank to this recursive formulas, that became popular 
with the works of Benoît Mandelbrot in the 70th of last century, it has been 
possible to give a mathematical formalization of several natural phenomena, 
from the growing process of snow crystals to the  shape of threes.2 Some years 
later Donald Tomalia and co-workers translated the same concepts to 
chemistry and to synthesized3 and patented4 polymers with star or tree shapes, 
built like onions, where the functional groups on each layer constituted  the 
substrate for the synthesis of a subsequent outer one.  
Because their shape, Tomalia named this molecules dendrimers, after 
δηνδρον meaning a tree in Greek. At the same time, Newkone’s group 
independently reported synthesis of similar macromolecules.5 They called them 
arborols from the Latin word 'arbor' also meaning a tree. The term cascade 
molecule is also used, but 'dendrimer' is the best established one. 
As often happens with brand new class of compounds, new symbolism had 
to be introduced to represent them. As will be seen in more details in the 
paragraph expressed dedicated to synthesis, two main  synthetic ways are 
used: convergent6 and divergent.7 
Alike with linear polymers, dendrimers must not arise from a single kind of 
monomers, copolymers are often more suitable for specific application.8 
Dendrimeric copolymers are a specific group of dendrimersdivided in two 
classes: 
• Segment-block dendrimers9 are built with dendritic segments of 
different constitution. They are obtained by attaching different wedges 
to one polyfunctional core molecule. 
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• Layer-block dendrimers10 consist of concentric spheres of differing 
chemistry. They are the result of placing concentric layers around the 
central core. 
 
 
Scheme 4.1: Segment (A) and layer (B) block dendrimers 
4.1.2 Properties 
It could be expected, and actually happens, that the properties of highly-
branched macromolecules can be very different from linear polymers, which 
only occasionally contain some smaller or longer branches. The peculiar 
characteristics of a dendrimer respect to a linear polymer are: 
• Molecular uniformity: Dendrimers are monodisperse macromolecules, 
unlike linear polymers. The classical polymerization process which results 
in linear polymers is usually random in mature and produces molecules 
of different sizes, whereas size and molecular mass of dendrimers can be 
specifically controlled during synthesis 
 
• Multifunctional surface: Because of their compact tree-like molecular 
structure, they provide a rich source of surface functionality which 
makes them useful building blocks and carrier molecules at the 
nanometer level. Lower generation dendrimers which are large enough 
to be spherical but do not form a highly packed surface, have enormous 
surface areas in relation to volume (up to 1000  m2/g)11 
  
 
 
    71 
 
• Spherical shape: In solution, linear chains exist as flexible coils; in 
contrast, dendrimers form a tightly packed ball. This has a great impact 
on their rheological properties. Dendrimer solutions have significantly 
lower viscosity than linear polymers12 
 
• Internal cavities: Presence of internal cavities give them the possibility to 
encapsulate guest molecule in the macromolecule interior. Meijer and 
co-workers13 trapped small molecules inside the 'dendritic box', then a 
shell was formed on the surface of the dendrimer by reacting the 
terminal functionalities and guest molecules were stably encapsulated 
inside the box. Cleavage of the outer shell could liberate the guest 
molecules14. Particular interesting is the possibility of a photochemical 
opening and closing this boxes.15 
 
 
Scheme 4.2: “dendritic box” encapsulating guest molecules & photochemical open-close mechanism  
 
• Light harvest:16 Probably the most recent peculiar characteristic of 
dendrimers is their ability to act as extremely efficient light-harvesting 
antennae,17 extremely useful in laser-dye experiments.18 
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4.1.3 Applications 
There are nowadays more than fifty families of dendrimers, each with 
unique properties, since the surface, interior and core can be tailored to 
different sorts of applications. The increase of their importance can be easily 
judged by the number of released patents dealing with this species, that soared 
from two in the period between 1981-1985 to more than one thousand in last 
lustrum.19 
This application can be sorted in three main areas: 
• Commodity application supplementing and hopefully “pulling” more 
exotic applications in nanotechnology and biomedicine, as have been the 
use of dendrimers as additives in commodity plastics and in ink/toner 
industry 
 
• Pharmaceutical and biotechnological, as delivers of drugs and other 
therapeutic agents that can be locked in dendrimers interiors as well as 
attached to the surface groups 
 
• Applied research arising from basic “proof of concept” or mere 
interesting synthetic chemistry. It is a composed group whose more 
present application is in industrial processes as nanoscale catalyst,20 
where thanks to dendrimers it is possible to combine the advantages of 
homogeneous and heterogeneous catalysis.21 
Of this plethora of uses,22 the more akin and relevant for my study is the 
use of copper and rhenium complexes for RIT23 and of complexes of 
gadolinium, an heavy lanthanide whose dimension are not too different from 
An, as contrast agent for Magnetic Resonance Imaging (MRI), the diagnostic 
equivalent of NMR, that detect the NMR signal of aqueous protons, and as 
consequence water concentration, in tissues.24  Addiction of contrast agents 
(paramagnetic metal cations) improves the sensitivity and specificity of the 
methodology. Gadolinium salt of diethylenetriaminepentaacetic acid (DTPA) is 
used clinically but it diffuses into the extravenous area due to its low molecular 
mass.25 Dendrimers due to their properties are highly suited for use as image 
contrast media. Several groups have prepared dendrimers containing 
gadolinium ions chelated on the surface.26, 27  
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4.1.4 Synthesis 
Dendrimers are generally prepared using either a divergent method of a 
convergent one:28 
• Divergent methods,29 where dendrimers grow outwards from a 
multifunctional core molecule. 
 
 
Scheme 4.3: Dendrimer divergent synthesis 
The core molecule reacts with monomer molecules containing one 
reactive and two dormant groups giving the first generation dendrimer 
(propagation step). Then the new periphery of the molecules is activated 
for reactions with more monomers (deblocking step). The product of this 
reaction becomes the new dendrimer core, the process is repeated for 
several generations and the dendrimer is built layer after layer. This 
approach is successful for the production of large quantities of 
dendrimers. Problems occur from side reactions and incomplete 
reactions of the end groups that lead to structure defects. To prevent 
side reactions and to force reactions to completion large excess of 
reagent is required, that causes some difficulties in the purification of the 
final products. 
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• Convergent methods,30 were developed as a response to the 
weaknesses of the divergent synthesis. Also in the convergent approach 
the dendrimer is constructed stepwise, but this time starting from the 
end groups and progressing inwards. When the growing branched 
polymeric arms, called Dendrons, are large enough, they are attached to 
a multifunctional core molecule. 
 
 
Scheme 4.4: Dendrimer convergent synthesis: Propagation step 
The convergent growth method has several advantages. Desired 
products are relatively easy to purify and the occurrence of defects in the 
final structure is minimized. It becomes possible to introduce subtle 
engineering into the dendritic structure by precise placement of 
functional groups at the periphery of the macromolecule. Its limit is that 
it does not allow the formation of high generations because steric 
problems occur in the reactions of the dendrons and the core molecule, 
Scheme 4.6. 
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• Self-assembling methods,31 were used by Zimmerman’s group32 to 
synthesize large quantities of high generation dendrimers. They prepared 
wedge-shaped molecule with adendritic tail in such a manner that 
subunits could self-assemble in bigger aggregates. Wedges are held 
together by hydrogen bond and stabilized by van der Waals  interactions. 
This non-covalent structure33 is responsible for the limit stability of this 
kind of structures, that disaggregate in diluted solutions, polar solvents 
and when the temperature is raised. 
 
It is worth to note that two decade since the discovery of dendrimers the quite 
artisan-like multi-step synthesis still require great effort. Though DSM 
advocates more cost-friendly, large-scale dendrimers production with the 
ASTRAMOL™ technology,34 only few applications, for which the unique 
dendrimers structure is crucial to pass the cost-benefit test. It is quite trivial to 
say that most of them are in the pharmaceutical field. 
∗ ∗
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G(n+1) dendron G(n+1) dendron
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4.2 Identification of the target D-BCAs 
 
As with other classes of polymers, dendrimers are extremely versatile and can 
be tailored on the custom exigencies to obtain the maximum efficiency from 
their use. In this paragraph the characteristics of the various dendrimer 
constituents will be scrutinized to arrive to the identification of suitable target 
molecules. 
4.2.1 The chelating functional group 
As said in paragraph 1.3, Ac+++ is an hard cation that has stronger interactions 
with hard anions. Among the electron donating groups stable in water solution 
(blood, where the complex will find its final application, is a highly complex 
water solution), the carboxylic one seems to be the more suitable. It is negative 
charged but does not displace hydrogen atoms from water molecules as 
alcoholates or amides do, and being harder than thiolates is a better chelating 
atoms toward An, even if the thiolates have an higher nucleophilicity. 
Anionic dendrimers can be used in livings. While “cationic” dendrimers (e.g. 
amine terminated PAMAM and poly(propylene imine) dendrimers that form 
cationic groups al low pH) are generally haemolytic and cytotoxic and their 
toxicity is generation dependent and increases with the number of surface 
groups35, anionic dendrimers (like those bearing a carboxylated surface) are not 
cytotoxic over a broad concentration range.36 
Carboxyl group can be both inserted on the dendrimer surface at the end of the 
synthesis using dendrimeric superficial functional groups in a specific synthetic 
step or, because of the high versatility of carboxylic acids and their derivatives,  
be a functional group of the monomer, allowing more straightforward 
syntheses. 
Since An have a coordination numbers between 6 and 10, a number of 
complexing groups in the same range must be present on the target molecules 
to form a complex with one metal atom, and between 12 and 20 functional 
groups are required to complex two actinides atoms. Since BCAs that can bring 
a load of just one Ac atom have already been synthesized,37,38 syntheses of 
double-load BCAs have more practical interest. Unfortunately double loaded 
classic Pendant Type Macrocyclic Bifunctionalized Chelating Agents (PT-MBCA) 
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are really difficult to be synthesized and a new approach toward this problem 
has to be sought. The target at this initial stage is to prove the feasibility of D-
BCA of n-generation (Gn) with around eight chelating functional groups to open 
the way to D-BCA of n+1 generation (with around 16 chelating functional 
groups) able to bring a load of two An atoms. 
4.2.2 The Ig binding functional group 
In § 1.5 we have seen that several functional groups can be use to covalently 
bind the Ig to the Chelating Agent. Isothiocyanate, that reacts quickly and 
selectively with an amino group to give substituted thiourea,39 is the most 
interesting one.  
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Scheme 4.5: synthesis of Isothiocyanate 
It can be easily produced starting from an amine and thiophosgene, along the 
synthetic path shown in Scheme 4.5, requiring just a free aminic functionality 
to be inserted in the BCA, Scheme 4.6. 
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On a synthetic standpoint both solutions should be possible, since 
dendrimers of low generations (0th, 1st, 2nd and 3rd) have highly asymmetric 
shape and possess more open structures as compared to higher generation 
dendrimers. As the chains growing from the core molecule become longer and 
more branched (in 5th and higher generation) dendrimers adopt a globular 
structure40 and with this dendrimers the use of a pendant, that come out from 
the globular structure, were unavoidable. 
 
 
 
Scheme 4.6: Rapresentation of a typical sturburst dendrimer possessing terminal carcoxylate 
groups: generation 1.5-5.5. Note the congestion of the surface groups that increases as the 
generation size increase. 
In the already synthesized  BCA both solution have been taken, i.e. some 
use one of the chelating group to create a covalent bond with the antibody, 
avoiding the use of any pendant,  others use a pendant41 -usually a benzyl 
group that form a large conjugation with the thiourea giving rise to a long rigid 
group that keep the chelating  agent far from the antibody. Since this group has 
been proved effective, it makes sense to use it as first trial.  
Since the introduction of the isothiocyanate group makes the whole 
synthesis notably more complex, a wise solution is to prove the feasibility of a 
D-PT-BCA step by step: First prove that dendrimers forms complexes with An. 
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Then prove that dendrimeric steric hindrance allows the introduction of a 
pendant. Third step will be the demonstration that the pendant itself does not 
interfere with the chelating properties of the dendrimer. Finally the 
Isothiocyanate group will be introduced. Since the report of Diallo proved the 
suitability of dendrimers as complexing agents for An, the target of this work 
became to prove that dendrimeric steric hindrance allows the introduction of a 
pendant. 
4.2.3 The monomer 
From the previous paragraphs come out that our target D-BCAs should have 
around 16 carboxylic functionalities and at list one free amino group, it would 
make sense to have the same functionalities already present on the monomer, 
to avoid synthetic steps expressly dedicated to their introduction. In nature 
there are a lot of molecules that present at the same time a carboxylic and an 
aminic functionality: the amino acids. Of the 20 more common amino acids 
used by living beings for protein synthesis, and that are excellent organic 
synthesis starting materials because of their availability and their cheap costs, 
only two, aspartic and glutamic acid (Asp and Glu respectively, Fig. 4.1), have 
two carboxylic functionalities that make them suitable as building block for the 
synthesis of a dendrimer akin to the target one. 
NH2
O
HO
OH
O
Asp
NH2
O
HO O
OH
Glu
 
Fig. 4.1: Aspartic (Asp) and glutamic (Glu) amino acids. 
The two amino acids differ in a chain carbon atom, so they show the same 
reactivity and the choice has to be taken on the basis of a shorter or longer 
alkyl backbone. On one side, having more methylenic groups implies a bulkier 
D-BCA that can give heavier interference with the quaternary structure of the 
Ig and compromise its binding ability toward its antigen. This would bent the 
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scale on the side of aspartic acid. On the other hand longer branches would 
allow a more comfortable allocation of carboxylic groups around the An ions, 
bringing higher stability constants and a safer use of the produced drug. Since 
the latter is the most important parameter, the first attempt is the synthesis of 
a glutamic acid based D-BCA.  
Theoretically it could also be proposed to start with an amino acid with other 
functional groups, but their introduction would signify the introduction of other 
reactivity that would complicate the synthesis bringing no advantage. Also the 
choice of an amino acid with more amino groups would have brought no 
advantage, since carboxylic functionalities are required on the dendrimeric 
surface. 
4.2.4 The core 
There is no need to use as central molecule a different specie than glutamic 
acid itself. It has an amino group that can be used for the direct introduction of 
the Isothiocyanate group or of a pendant moiety, and eight carboxylic groups 
are exactly expressed on the surface of the third generation of a pure Glu 
dendrimer. 
4.2.5 The target molecule 
From the previous paragraphs come out that the target molecule is a 3th 
generation dendrimer of the glutamic acid. Monomers can be built together 
using peptidic bounds. There are arguments that speak in favor and 
counterarguments to this choice. On one side this kind of compounds are 
ubiquitously spread in our organism and they are surely not toxic, on the other 
one they could be recognized by the immune system as non-self and elicit an 
immunogenic reaction. Actually some synthetic polypeptides do and other 
don’t, and no universally valid prevision can be made on if, how strong and 
how much time an immune response would take to appear. Only experiments 
on the product can give a clear answer. 
All the characteristic of the target molecule have been at this point defined: 
the monomer, the generation number, the core, the pendant and its position. 
Assembling all the puzzle tesseræ together give the identikit of the target 
molecule: 
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Fig. 4.2: Target Dendrimeric Chelating Agent  
A peculiar symbolism has been established for amino acids based dendrimers, 
recalling that in use for protein. In the letter amino acids are written in left-
right direction with the amino group on left and the carboxylic termination on 
the right. In the symbolism adopted for amino acid based dendrimers the 
substituent linked to the amino group are written on left end,  followed by the 
amino acid type (in parenthesis) and the specification of the generation 
preceded by a capital G. Finally carboxylic substituents are written on the right 
end. The target molecule for instance is written Bz-(Glu)G3-OH, meaning a 
three generation Glutamic acid dendrimer with a benzoyl functional group 
linked to the terminal amine and carboxylic acid on the surface terminations. 
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4.3 Identification of the synthetic strategy 
Once that the target molecule has been chosen, the disconnection approach 
(Schemes 4.7-4.10) was used to identify the better reaction sequence that lead 
to its synthesis.  
 
Scheme 4.7: Retrosinthetic analysis of the target molecule. 
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First step is the disconnection of the benzoic group, to leave an 
homogenous molecule composed only by glutamic acid monomers. This lead 
on one side to a benzoic synthon, that in the actual synthesis can be replaced 
by bezoyl chloride synthetic equivalent, and on the other to a third generation 
polypeptidic dendrimer with a free terminal amino group.  
To avoid the formation of the mixed anhydride, acidic functionalities must 
be protected. The esteric functionality has been chosen for this aim because it 
is an excellent protective group and allows the use of diethyl glutamate (31), a 
commercially available product, as starting material. 
 
Scheme 4.8: Retrosynthesis of the target molecule 
When a dendrimer is to be synthesized the first choice –except some very 
exotic procedures- is between convergent and divergent methods. The most 
sensible disconnection in a polypeptidic dendrimer is on the amidic bounds. In 
the following schemes double waved lines lead to convergent approach 
synthesis disconnection path while single lines lead to a divergent approach 
disconnection path.  
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Scheme 4.9: Convergent and divergent disconnection of H-(Glu)G3-OEt. Single XXX 
Product 31 is the commercially available diethyl glutamate. To find the 
synthetic equivalents of synthons H-(Glu)G2-X (32) and H-Glu-X (33) the generic 
X groups can be replaced by hydroxyl groups (a plenty of peptidization 
reactions between amines and carboxylic acids are well known),42 and amino 
groups have to be protected. Di-ter-butyl dicarbonate (BOC)43, that can be 
easily inserted and deblocked, is used in several commercially available 
products, will be used each time an amino group has to be protected in this 
reaction sequence. The used synthetic equivalent for product 33 is the 
commercially available Boc-Glu-OH . Product 36 and H-(Glu)G2-OEt (34) have to 
undergo to a further retrosynthetic step.  
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Scheme 4.10: Retrosynthesis of the target molecule 
If, like in the previous retrosynthetic step, X groups in the synthons 33 and 
BOC-Glu-X (37) are replaced by hydroxyl groups and the amino group in 33 is 
protected using BOC, it becomes clear that they share a common synthetic 
equivalent, the already used commercial BOC-Glu-OH. Protecting carboxylic 
acids in Glu with ethyl esterification, it becomes also clear that 31 is its 
synthetic equivalent. 
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Two feasible paths for the synthesis of the target molecule starting from 
commercially available molecules have been identified by this retrosynthetic 
analysis. Corresponding convergent and divergent direct syntheses are shown 
respectively in schemes 4.11-4.14. 
 
 
Scheme 4.11: Retrosynthesis of the target molecule 
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Scheme 4.12: Divergent Synthetic path to Bz-(Glu)G3-OEt 
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Scheme 4.13: Conergent Synthetic path to Bz-(Glu)G3-OEt 
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Scheme 4.14: Convergent Synthetic path to Bz-(Glu)G3-OEt 
Multi-step reactions used for dendrimers are a kind of controlled 
polymerization, and like in polymerization processes we can identify initiation, 
propagation and termination reactions that take place in the reaction vessel, 
also in the case of dendrimer initiation, propagation and termination reaction 
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steps can be identified. Of utmost importance for efficient synthesis planning is 
the identification of a recursive “propagation” steps sequence, where 
generation n dendrimer reacts to give the homologue of generation n+1. In the 
divergent Synthesis this cycle is identified by growth step (reaction with 
monomer as in [1], catalyzed by EDC and HOBt) and deblocking (in this case of 
esteric protective groups with LiOH,44 as in [2]). The convergent synthesis 
present a recursive cycle with the same growth step, but this time is the BOC 
protective group that is deblocked using first TFA45, 46 and than triethylamine to  
neutralize the solution, as in reaction [6]. 
Both synthetic pathways can be followed and would lead to the target 
molecule, but convergent approach, that minimizes defects in the final 
structure and allow an easier recovery of the final product, is used. If the target 
molecule would have been an 6th or higher generation this approach would 
have not been possible because of steric hindrance around the core molecule.38 
In conclusion this synthetic path lead to the preparation of the protected 
form of Bz-(Glu)G3-OH (Bz-(Glu)G3-OEt), with a global process yield of 34%. 
This product will be deblocked and its chelating properties toward Ac+++ 
assessed in a facility entitled to work with radioactive materials. 
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Chapter 5 
 
 
Experimental Part 
 
 
5.1 General Methods and Materials 
5.1.1 Purification of solvents and reagents 
All syntheses were carried out in air unless otherwise stated. 
Chloroform, Methylene chloride used for synthesis were dried on Calcium 
hydride and distilled under nitrogen after the use. 
5.1.2 Instruments 
Thin-layer chromatography was performed with pre-coated silica gel plates 
(DC-Alufolien Kieselgel 60 F254, Merk KGaA, Darmstadt, Deutschland). 
pH measurements have been performed either with litmus 435140 (Carlo Erba, 
Rodano, Italy) or with a pH-meter Hanna pH tester checker 1 (Hanna 
Instruments, Woonsocket, RI). 
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Gaschromatographic analyses were performed on a Perkin-Elmer (Waltham, 
Massachusetts) 8500 or on a Perkin-Elmer Clarus 500 gaschromatograph 
equipped with a split-splitless injector and a FID detector, using a capillary 
column ZB-1 (15m*0.25 mm, film thickness 0.25 μm), and nitrogen as carrier 
gas. 
 
Mass spectra were recorded either on an Agilent (Santa Clara, California) 
5995A spectrometer, interfaced with an Agilent 5980 gas chromatograph 
equipped with a split-splitless injector and a ZB-1 column (30m x 0.25mm, film 
thickness 0.25 μm), using He as carrier gas; or on a Shimadzu Axima-CFR 
MALDI-TOF (Kyoto, Japan). 
 
Uncorrected Melting points (mp) were determined on a Koffler Heizbank 
Reichert Thermovar 18.43.21. 
Infrared spectra have been acquired on a Perkin-Elmer 1605 FT-IR 
1H and 13C-NMR spectra were recorded on a Varian Gemini-200 NMR 
spectrometer at the frequencies of 200 MHz for 1H and 50 MHz  for 13C, or on a 
Varian VXR-300 at the frequencies of 300 MHz for 1H and 75 MHz  for 13C. 
Chemical shift measurements have been determined at room temperature (∼ 
25 °C) unless otherwise stated and are referred to TMS or to solvent as internal 
standard. 
5.2 Synthesis of PT-HEHA-CA 
5.2.1 Synthesis of methyl 2-amino-3-(4’-nitrophenyl)propanoate 
 
 
 
2-amino-3-(4’-nitrophenyl)propanoic acid (320 mg, 1.5 mmol) was 
suspended into 2,2-dimethoxypropane (22.5 cm³). Concentrate Hydrochloric 
acid (1.5 cm³ 36%)  was added to this stirring mixture, and the reaction was 
N
O
O
H2N
COOMe
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further carried on at room temperature for 17 h. During this time the solution 
darkened considerably. 
The evaporation of the solvent and lither products at reduced pressure 
gave a yellow precipitate, that was dissolved in anhydrous Methanol and 
precipitated by the addition of  anhydrous diethyl ether. After filtration the 
product was dried under vacuum and the oily product was recovered (260 mg, 
1.5 mmol) in quantitative yield. 
1H-NMR  (200 MHz, CDCl3): δ 8.23 (2H, d, J=0.09, H-Ph-CH2); 7.48 (2H, d, J=0.04, 
NO2-Ph-H); 4.48 (1H, t, J=0.03, -CH2-CH(NH2)-COOCH3); 4.12 (2H, s, NH2); 3.78 
(3H, s, COOCH3); 3.39 (2H, dd, -Ph-CH2-CH(NH2)-COOCH3). 
 
13C-NMR  (200 MHz, CDCl3, ): δ 169.2 (g);  146.9 (d); 
141.4 (a); 130.1 (c); 123.8 (b); 53.2 (f); 53.1 (e); 34.9 
(h). 
IR (KBr, cm-1): 2919, 2673, 2626, 1743, 1604, 1513, 1491, 1450, 1347, 1237, 
1181, 1145, 1105, 1058, 979, 947, 931, 865, 856, 842, 809, 750, 700, 652, 506, 
489. 
GC (140°C/5’ @ (30°C/min) 280°C, solvent THF, column 15m, DB1, P=8 atm, 
Injector 220°C, Detector 240°C). t=7.83 min. 
MS (m/z): 165 (50), 137 (8), 119 (20), 88 (100). 
 
 
5.2.2 Synthesis of methyl 2-((methoxycarbonyl)methylamino)-3-(4’-  
 nitrophenyl)propanoate 
 
 
 
NO2
NH
MeOOC
MeOOC
dO2N a
b c
e
f
g
O
h
NH2
O
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Methyl 2-amino-3-(4’-nitrophenyl)propanoate (500 mg, 1.8 mmol) was 
dissolved under Nitrogen atmosphere in 50 cm³ of anhydrous THF. To the 
stirring solution were added three equivalents of Triethylamine (0.75 cm³, 5.4 
mmol) and three equivalents of methyl 2-bromoacetate (0.5 cm³, 5.4 mmol). 
After stirring at room temperature (2.5 h) the yellow solution was washed 
several times with water. The phases were separated and the aqueous one 
washed with methyl acetate. After drying with sodium sulphate, the solution 
were concentrated under vacuum to give 533 mg (1.15 mmol) of a yellow oil 
with a 64% yield. 
 
1H-NMR (200 MHz, CDCl3): δ 8.18 (2H, d, J=0.05, H-Ph-NO2); 7.42 (2H, d, J=0.05, 
H-Ph-CH2); 3.72 (6H, s, O-CH3); 3.65 (1H, t, J=0.03, -NH-CH(COOMe)-CH2-); 3.42 
(2H, d, J=0.01, -CH2-COMe); 3.32-3.18 (2H, m, Ar-CH2-CH-); 2.1 (1H, s, -NH-). 
 
 
13C-NMR  (200 MHz, CDCl3): δ  173.6 
(g);  172.0 (j); 147.1 (a); 145.0 (d); 
130.2 (c); 123.7 (b); 61.6 (f); 52.2 
and 52.0 (h-k); 49.0 (i); 39.2 (e).  
 
 
IR (KBr, cm-1): 3455, 3336, 2948, 2850, 1734, 1600, 1519, 1432, 1346, 1206, 
1109, 1011, 985, 855, 742, 699, 650. 
 
GC (140°C/5’ @ (30°C/min) 280°C (15’), solvent THF, column 15m, DB1, P=8 
atm, Injector 220°C, Detector 240°C). t=10.15 min. 
 
MS (m/z): 297 (M+1, 1), 237 (M-COOMe, 65), 160 (M-NO2-Bz, 100), 100 (M-
NO2-Bz –COOMe, 50). 
 
 
 
 
b
a
d
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e
NO2
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5.2.3 Synthesis of 3-(4’-nitrobenzyl)-2,6-dioxo-1,4,7,10,13,16-
 hexaazacyclooctadecane 
 
 
HN
HN
HNNH
NH
NH
O
O
NO2
 
 
 
To a stirring solution of sodium methoxide (2.2 cm³ 0.5 M, 1.1 mmol) in 
anhydrous THF (250 cm³), a solution of 1,11-diamino-3,6,9-triazaundecane (0.2 
cm³, 1 mmol) in anhydrous THF is added, under Nitrogen atmosphere. After 1 h 
at the reflux of the solvent, 2-((methoxycarbonyl)methylamino)-3-(4’-
nitrophenyl)propanoate (290 mg, 1.0 mmol) dissolved in anhydrous THF is 
added. After  96 h the solvent is evaporated at reduced pressure and the 
product suspended in Chloroform, filtered and purified by flash 
chromatography (Acetone/pentane = 20/80). The red-brick solid product (82 
mg, 0.19 mmol) was recovered after evaporation of the solvents under vacuum 
with a 20% yield. 
 
1H-NMR (200 MHz, CDCl3): δ 8.16 (2H, d, J=0.05, H-Ph-NO2); 7.54 (1H, s, -NH-
CO-); 7.39 (2H, d, J=0.05, H-Ph-CH2); 7.25 (1H, s, -NH-CO-); 3.92 (1H, t, J=0.04, 
NO2-Bz-CH-(CO-)NH-); 3.51-2.79 (12H, m); 2.69 (8H, s, -NH-CH2-); (3H, s, NH). 
 
13C-NMR  (200 MHz, CDCl3): δ  170.4 (g);  168.8 
(p); 145.3 (a); 144.9 (d); 128.0 (c); 120.3 (b); 62.8 
(f); 50.4 (j-m); 49.9 (i,n); 49.6 (q); 44.1 (h,o); 36.7 
(e).  
gHN
HN
f
HN p
q
NH
n o
hi
NHj
k
NH
l
m
O
O
e
d
ab
c
NO2
IR (KBr, cm-1): 3278, 2963, 2854, 1658, 1514, 1458, 1341
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5.2.4 Synthesis of 2-amino-N-(2’-aminoethyl)-3-(4’-nitrophenyl)propanamide 
 
N
O O
NH2
O
N
H
NH2
 
A solution of 1,2-diaminoethane (7.0 cm³, 130 mmol) is slowly added to a 
stirring solution of 2-amino-3-(4’-nitrophenyl)propanoate (450 mg, 2 mmol) in 
methanol (40 cm³). The solution is stirred at room temperature for 18 h and 
the solvent is evaporated at reduced pressure to give brown solid product (460 
mg) quantitatively. 
 
1H-NMR (200 MHz, CDCl3): δ 8.19 (2H, d, J=0.04, H-Ph-NO2); 7.68 (1H, s, -NH-
CO-); 7.41 (2H, d, J=0.05, H-Ph-CH2); 3.67 (1H, m, NH2-CH-CO-); 3.47 (2H, s, NH-
CH2-CO-); 3.39-2.75 (8H, m, 2CH2, 2NH2). 
 
13C-NMR  (200 MHz, CDCl3): δ 173.7 (g);  147.2 (a); 146.0 (d); 130.4 (b); 123.9 
(c); 56.3 (f); 42.0  (e); 41.6 (h); 41.1 (i). 
 
 
IR (KBr, cm-1): 3360, 2930, 2861, 1660, 1644, 1598, 1343, 1106, 857, 744, 700. 
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5.3 Synthesis of nitrogenated macrocyclic chelating agents 
5.3.1 Synthesis of 1,4,8,11-tetraparatoluenesulphonyl-1,4,8,11-
tetraazacyclotetradecane 
 
 
Paratoluenesulfonyl chloride (5.0 g, 
25 mmol) dissolved in Chloroform 
(50 cm³) was slowly added to a 
stirring basic aqueous solution (12 g 
NaOH in 50 cm³ of water) containing 
1,4,8,11-tetraazacyclotetradecane 
(1.0 g, 5 mmol) and a catalytic 
amount of Triton B. 
After 18 h the reaction was interrupted, the phases separated and the product 
crystallized by addition of diethyl ether to the organic one. After filtration the 
white crystals were recovered with a 97.5% yield. 
 
1H-NMR  (200 MHz, CDCl3): δ 7.79 (8H, d, J=0.05, H-Ph-SO2); 7.42 (8H, d, J=0.05, 
CH3-Ph-H); 3.30 (8H, s, N-CH2-CH2-N); 3.22 (8H, t, J=0.03, (CH2)2-CH2-N); 2.52 
(12H, s, -Ph- CH3); 1.96 (4H, t, J=0.03, CH2-CH2-CH2-). 
 
13C-NMR  (200 MHz, CDCl3): δ  144.0 
(i);  134.5 (f); 130.0 (h); 127.6 (g); 
50.0 (a); 48.1 (b); 27.8 (j); 21.6 (c).  
 
 
IR (KBr, cm-1): 3066, 2922, 2869, 1597, 1459, 1341, 1159, 1090, 914, 814, 732, 
549. 
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5.3.2 Synthesis of 1-(bromomethyl)-4-nitrobenzene 
NBS (360 mg, 0.5 mmol) is added to a solution of p-nitrotoluene (276 mg, 0.5 
mmol) in CCl4 (100 cm³) a solution of. After 3 h at the reflux of the solvent the 
precipitate is filtered and the solvent evaporated at reduced pressure. The 
reaction gave the product (89 mg, 0.4 mmol) with a 83% yield. 
 
1H-NMR  (200 MHz, CDCl3): δ 8.25 (2H, d, J=0.05, H-Ph-NO2); 7.59 (2H, d, 
J=0.05, CH2-Ph-H); 4.54 (2H, s, CH2Br). 
 
 
13C-NMR  (200 MHz, CDCl3): δ  147.9 
(a);  143.5 (d); 129.3 (c); 120.7 (b); 
34.0 (e). 
 
a
d
c
bN
O
O
e
Br
MS (m/z): 217 (M+ +1, 6.3), 215 (M+ -1, 6.4), 136 (100.0), 106 (12.2), 90 (23.9), 
89 (28.4). 
5.3.3 Synthesis of 1,4,8,11-tetra-N-nitroso-1,4,8,11-tetraazacyclotetradecane 
with NaOH 
 
N
N
N
N
ON NO
NOON
 
 
In 200 cm3 of water, 1,4,8,11-tetraazacyclotetradecane (1.0 g, 5.0 mmol) is 
dissolved. The solution is acidified (pH = 2.5) with concentrated hydrochloric 
acid (1.6 cm3) and cooled to 4 °C. A water solution of sodium nitrite (1.53 g, 22 
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mmol in 10 cm3 of water) is slowly added. The pH is kept between 5.0 and 5.5 
with the addition of glacial acetic acid. After 2h the precipitate, separated from 
the solution and washed with cold water, was dried. The product  (1.14 g, 3.6 
mmol) was recovered in 72% Yield. 
 
1H NMR (200 MHz, DMSO): δ 4.68 – 3.34 (16 H, m, -NH-CH2-CH2-CH2-NH-); 
2.48 (4 H, m, -NH-CH2-CH2-CH2-NH-, 1st conformer); 2.20 (4 H, m, -NH-CH2-CH2-
CH2-NH-, 2
nd conformer); 1.89 (4 H, m, -NH-CH2-CH2-CH2-NH-, 3rd conformer); 
1.64 (4 H, m, -NH-CH2-CH2-CH2-NH-, 4th conformer). 
IR (KBr, cm-1): 2955, 1450, 1366, 1339, 1311, 1272, 1139, 1022, 966, 885, 811, 
789, 650, 555. 
Mp = 211 °C 
 
5.3.4 Synthesis of 1,4,8,11-tetra-N-nitroso-1,4,8,11-tetraazacyclotetradecane 
with Dinitrogen tetroxide (ipoazotite): 
 
Ipoazotite, produced by extremely slow addition of oil of vitriol to sodium 
nitrite (22.3 g, 0.32 mmol), is bubbled into a water solution of 1,4,8,11-
tetraazacyclotetradecane (218 mg, 1.1 mmol in 100 cm3 water). After 4 h, when 
no more fumes are produced, the reaction is interrupted, the colourless 
precipitate is filtered, washed with cold water and dried. 
By spectroscopy analyses it is identified as the target molecule. Yield: 227 mg, 
0.7 mmol, 68%.  
 
5.3.5 Synthesis of 1,4,8,11-tetra-N-nitroso-1,4,8,11-tetraazacyclotetradecane 
(7) via Amberlist and silica wet: 
 
1,4,8,11-tetraazacyclotetradecane (1.73 g, 8.7 mmol) is dissolved Into a stirring 
reaction mixture composed by wet silica (21.7 g, 330 mmol of silica in 200 cm3 
water), methylene chloride (200 cm3), Amberlist 15 (12.2 g) and sodium nitrite 
(6.26 g, 91 mmol). When no more fumes evolves (6 h) the reaction is 
interrupted and the mixture filtered. By soxhlet extraction (Acetonitrile for 16 
h) only a poor quantity (104 mg, 0.5 mmol) of the original reactant (1,4,8,11-
tetraazacyclotetradecane) is recovered. 
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5.3.6 Synthesis of 1,4,8,11-tetra-N-nitroso-1,4,8,11-tetraazacyclotetradecane 
with trimethylnitrososilane: 
Chlorotrimethylsilane (0.8 cm3, 6 mmol) is add to a stirring solution of sodium 
nitrite (310 mg, 4.5 mmol) in methylene chloride (30 cm3). After 30 minutes a 
pale yellow solution of 1,4,8,11-tetraazacyclotetradecane (200 mg, 1 mmol) in 
methyl chloride (10 cm3) is carefully dropped into the stirring solution, followed 
by Sodium carbonate (2.0 g, 18 mmol). After 16 h the precipitate is isolated by  
filtration, washed with cold water and dried. At spectroscopic analyses the solid 
(230 mg, 0.73 mmol) is recognized as the target product with a 73% Yield. 
5.3.7 Synthesis of 1,4,8,11-tetra-N-nitroso-1,4,8,11-tetraazacyclotetradecane 
with Chlorotrimethylsilane: 
Chlorotrimethylsilane (0.8 cm3, 6.0 mmol) is added to a stirring solution of 
sodium nitrite (400 mg, 5.8 mmol) and 1,4,8,11-tetraazacyclotetradecane 
(200mg, 1mmol) in methylene chloride (50 cm3). After 19 h the reaction is 
stopped, the solid is filtered and washed with methylene chloride. After 
evaporation of the solvent under reduced pressure a colorless solid (165 mg, 
0.52 mmol) identified by IR spectroscopy as the target molecule, is collected 
with a 52% Yield. 
 
5.3.8 Synthesis of 1,4,8,11-tetraazacyclo-1,4,8,11-tetrachlorotetradecane 
 
An aqueous solution of 1,4,8,11-tetraazacyclotetradecane (200 mg, 1mmol in 
10 cm³ H2O) is added at room temperature Into an aqueous solution of NaClO 
(8 mmol in 10 cm³ H2O). After 1.5 h the precipitate is collected by filtration, 
washed with cold water and dissolved in acetone. After filtration the organic 
N
N
N
N
Cl Cl
ClCl
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phase was dried over anhydrous sodium sulfate and the solvent evaporated at 
reduced temperature, to leave a white solid (218 mg, 0.65 mmol) in a 65% 
yield. 
 
1H NMR (200 MHz, CDCl3): δ 3.31 (8H, s, -N-CH2-CH2-N-); 3.14 (8H, t, J=0.03, -N-
CH2-CH2-CH2-N-); 1.97 (4H, p, J=0.03 -N-CH2-CH2-CH2-N-). 
13C NMR (200 MHz, CDCl3): 63.68 (-N-CH2-CH2-N-); 60.1 (-N-CH2-CH2-CH2-N-); 
26.2 (-NH-CH2-CH2-CH2-NH-). 
IR (KBr, cm-1): 2967, 2878, 1455, 1433, 1344, 1283, 1022, 1044, 961, 911, 872, 
783, 628, 561, 517. 
 
5.3.9 Synthesis of 1,4,8,11-tetra-N-amino-1,4,8,11-tetraazacyclotetradecane in 
phase transfer conditions 
 
 
 
Palladium-on-carbon at 10% (1.0 g, Fluka) is suspended into a solution of 
1,4,8,11-tetra-N-nitroso-1,4,8,11-tetraazacyclotetradecane (316 mg, 1 mmol) in 
ethanol (10 cm3), cyclohexene (0.5 cm3, 5 mmol) and benzene (20 cm3). After 
2.5 h at the reflux of the benzene and 16 h at room temperature, the solid was 
separated by filtration and the solvents evaporated at reduced pressure to give 
a greenish oil (30 mg, 0.12 mmol) of the product in a 12% yield. 
1H NMR (200 MHz, CDCl3): δ 2.87 (8H, s, -NH2); 2.60 (8H, s, -N-CH2-CH2-N-); 2.48 
(8H, t, J=0.04, -N-CH2-CH2-CH2-N-); 1.53 (4H, p, J=0.04 -N-CH2-CH2-CH2-N-). 
13C NMR (200 MHz, CDCl3): 59.4 (-N-CH2-CH2-CH2-N-); 58.0 (-N-CH2-CH2-N-); 
22.0 (-NH-CH2-CH2-CH2-NH-). 
IR (KBr, cm-1): 3472, 3406, 2959, 1655, 1639, 1541, 1508, 1301, 1257, 1192, 
1022, 799, 668. 
N
N
N
N
H2N NH2
NH2H2N
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5.3.10 Synthesis of 1,4,8,11-tetra-N-amino-1,4,8,11-tetraazacyclotetradecane 
with Sodium borohydride: 
 
1,4,8,11-tetra-N-nitroso-1,4,8,11-tetraazacyclotetradecane (630 mg, 3 mmol) is 
suspended along with sodium borohydride (1.96 g, 51 mmol) in methanol (50 
cm3) at room temperature. After 3 h the reaction solution is brought at the 
reflux of the solvent for 40 h. The solution is filtered and the solvent is 
evaporated under reduced pressure. The solid dissolved in ethyl acetate was 
filtered and the solvent evaporated at reduced pressure. 560 mg of a white 
solid, that appeared to be the starting material, were recovered. 
 
5.3.11 Synthesis of 1,4,8,11-tetra-N-amino-1,4,8,11-tetraazacyclotetradecane 
with Titanium(III) chloride: 
 
1,4,8,11-tetra-N-nitroso-1,4,8,11-tetraazacyclotetradecane (660 mg, 2.0 mmol) 
is suspended along with Titanium(III) chloride (1.70 g, 34 mmol) in water (200 
cm3) at room temperature. After stirring (1 h) the mixture is cooled (3 h) and 
brought at room temperature for 19 h. The mucilage-looking solid is filtered 
and extracted with ethyl acetate. The organic phase is dried on anhydrous 
sodium sulphate. The solvent is evaporated under reduced pressure, giving rise 
to the greenish oily product (100 mg, 0.4 mmol) in a 20% yield. 
5.4 Synthesis of dendrimeric BCA  
5.4.1 Synthesis of BOC-G2-OEt  
 
EDC (1.5 g, 8.0 mmol) was added to 
a stirring mixture of Boc-Glu-OH (0.9 
g, 3.7 mmol) and HOBt (1.23 g, 
8.0mmol) in CH2Cl2 (50 cm³). At the 
same time in a separate flask H-Glu-
OEt•HCl (2.25 g, 9.0 mmol) was 
dissolved in CH2Cl2 (10 cm³) and 
Et3N (0.6 ml, 8.0 mmol) and than 
added to the stirring reaction 
mixture. 
HN
NH
O
O
O
O
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After 53h the solution was washed with: saturated aqueous solution (10%) of 
sodium bicarbonate,  aqueous solution (10%) of citric acid, saturated solution 
(10%) of sodium bicarbonate and finally water. 
The organic phase was dried over anhydrous sodium sulphate, filtered and 
after the removal of the solvent in vacuo gave a white solid, that was dissolved 
in MeOH and purified  by column chromatography (MeOH/CHCl3 = 1/9). After 
evaporation of the solvents under reduced pressure the white solid product 
(1.70 g, 2.8 mmol), was recovered in a 76% yield. 
 
1H-NMR  (200 MHz, CDCl3) δ:  7.82 (1H, d, J=0.06 NH); 7.60 (1H, d, J=0.06 NH); 
4.92 (1H, d, J=0.06 NH); 4.45 (2H, t, J=0.05, -NH-CHR-CO-);  4.12 (8H, q, -COO-
CH2-CH3); 3.51 (1H, t, J=0.04, -NH-CHR-CO-);  2.41-2.22 (6H, m, -NH-(CH)-CH2-
CH2-COO-);  2.20-2.04 (6H, m, -NH-(CH)-CH2-CH2-COO-);  1.33 (9H, s, Bu
t); 1.25 
(12H, t, J=0.03 -COO-CH2-CH3). 
13C-NMR  (200 MHz, CDCl3) δ:  172.8,  171.6, 171.5,  171.3, 154.0, 79.5, 61.2, 
59.5, 50.7, 50.5,  31.6, 31.2, 29.7, 29.4, 28.2, 27.3, 25.7, 25.9, 13.1. 
IR (KBr, cm-1): 3322, 2977, 2933, 1733, 1683, 1655, 1522, 1258, 1200, 1167, 
655. 
mp = 87 °C 
 
5.4.2 Synthesis of H-G2-OEt  
 
Trifluoroacetic acid (0.5 ml, 6.5 mmol) is added to a 
stirring solution of BOC-G2-OEt (1.51 g, 2.5 mmol) in 
CH2Cl2 (50 cm
3). After 2 h the solution is neutralized 
with Triethylamine (0.9 ml, 6.5 mmol) and washed with 
an aqueous solution of sodium bicarbonate (5%).  The 
organic phase was dried over anhydrous sodium 
sulphate, filtered and the solvent removed under 
reduced pressure to give the product (1.22 g) in 96% 
yield. 
1H-NMR  (200 MHz, CDCl3): 7.79 (1H, s, NH); 7.63 (1H, s, 
NH); 3.80 (2H, s, NH2); 4.42 (2H, t, J=0.05, -NH-CHR-CO-
);  4.15 (8H, q, -COO-CH2-CH3); 3.48 (1H, t, J=0.04, -NH-
NH2
NH
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CHR-CO-);  2.4-1.9 (12H, m, -NH-(CH)-CH2-CH2-COO-);  1.2 (12H, t, J=0.03 -COO-
CH2-CH3). 
 
13C NMR  (200 MHz, CDCl3): δ 172.8, 171.6, 171.5, 171.3, 61.2, 59.5, 50.7, 31.2, 
29.4, 28.2, 25.9, 13.1.  
IR (KBr, cm-1): 3609, 3324, 3324, 2977, 2933, 1733, 1683, 1655, 1522, 1258, 
1200, 1167, 655. 
mp = 90 °C. 
 
5.4.3 Synthesis of BOC-G3-OEt (3) 
 
 
EDC (380 mg, 2 mmol) was added to a 
stirring mixture of Boc-Glu-OH (230 mg, 0.9 
mmol) and HOBt (310 mg, 2 mmol) in CH2Cl2 
(50 cm³). At the same time in a separate 
flask H-G2-OEt (1.34 g, 2.2 mmol) was 
dissolved in methylene chloride (10 cm3) 
and than added to the stirring reaction 
mixture.  After stirring (40 h) the reaction is 
stopped and the solution undergoes the 
same workup used for generation G2. 
 
The organic phase is dried on anhydrous sodium sulphate and filtered. The 
crude was purified by column chromatography using a Chloroform/Methanol = 
95/5 solution. Removing the solvents under reduced pressure the waxy product 
(820 mg, 0.65 mmol) is obtained in 65% yield. 
1H NMR  (200 MHz, CDCl3): δ 7.88 (3H, d, J=0.04, NH); 7.66 (3H, d, J=0.04, NH); 
5.08 (1H, d, J=0.04, NH); 4.8-4.6  (7H, m, -NH-CHR-CO-); 4.32-4.06 (16H, m, -CO-
O-CH2-CH3); 2.53-2.32 (16H, m, -NH-CH-CH2-CH2-COOEt); 2.32-2.14 (6H, m, -NH-
CH-CH2-CH2-COO-); 2.04-1.84 (6H, m, -NH-CH-CH2-CH2-COO-); 1.43 (9H, s, Bu
t); 
1.33-1.21 (24H, m, -CO-O-CH2-CH3). 
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13C NMR  (200 MHz, CDCl3): δ 188.6, 172.7, 171.1, 154.0, 79.5, 62.2, 60.6, 53.5, 
51.5, 32.3, 30.7, 30.5, 29.3, 28.4, 27.0, 26.8, 14.1. 
IR (KBr, cm-1): 3324, 2984, 2928, 1738, 1683, 1650, 1529, 1264, 1250, 1204, 
1168, 653. 
MP = 110 °C. 
 
5.4.4 Synthesis of H-G3-OEt (4) 
 
 
Trifluoroacetic acid (1.0 cm³, 13 mmol) is 
added to a stirring solution of BOC-G3-OEt 
(540 mg, 0.43 mmol) in Methylene chloride 
(50 cm3). After 2 h the solution is neutralized 
with Triethylamine (1.8 cm³, 13 mmol) and 
washed with an aqueous solution of sodium 
bicarbonate (5%).  The organic phase was 
dried over anhydrous sodium sulphate, 
filtered and the solvent removed under 
reduced pressure to give a pergameneous  
product (500 mg, 0.44 mmol) in quantitative 
yield. 
 
1H NMR  (200 MHz, CDCl3): δ 7.87 (3H, d, J=0.04, NH); 7.64 (3H, d, J=0.04, NH); 
4.7-4.5  (7H, m, -NH-CHR-CO-); 4.30-4.04 (16H, m, -CO-O-CH2-CH3); 3.93 (2H, s, 
NH2); 2.50-2.30 (16H, m, -NH-CH-CH2-CH2-COOEt); 2.30-2.12 (6H, m, -NH-CH-
CH2-CH2-COO-); 2.02-1.83 (6H, m, -NH-CH-CH2-CH2-COO-); 1.31-1.18 (24H, m, -
CO-O-CH2-CH3). 
13C NMR  (200 MHz, CDCl3): δ 188.9, 173.0, 171.4, 62.4, 60.8, 53.8, 51.7, 32.5, 
31.0, 30.5, 29.6, 27.2, 27.1, 14.3. 
IR (KBr, cm-1): 3613, 3324 ,3324, 2980, 2935, 1735, 1685, 1658, 1525, 1260, 
1205, 1170, 657. 
mp = 114 °C 
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5.4.5 Synthesis of Benzoil-G3-OEt (5) 
 
 
 
 
Benzoyl chloride (1.0 cm³, 0.8 mmol) 
diluted in Methylene chloride (10 
cm³) is slowly added to a stirring 
solution of H-G3-OEt (310 mg, 0.3 
mmol) in Methylene chloride (60 
cm³) and Triethylamine (1.0 cm³, 1.3 
mmol). After 16 h the solution is 
washed with a sodium hydroxide 
solution (5%) and then purified with 
a flash chromatography (Ethyl 
acetate/hexane = 20/80, then 
Methanol).  
 
After evaporation under reduced pressure a white waxy solid (260 mg, 0.21 
mmol) is obtained in 70% yield. 
1H NMR  (200 MHz, DMSO): δ 8.02 (2H, d, J=0.04, orto); 7.58-7.35 (3H, m, meta 
and para); 7.02 (3H, s, N-H); 6.74 (3H, s, N-H); 5.65 (1H, d, J=0.04, N-H); 4.72-
4.60  (7H, m, -NH-CHR-CO-); 4.17-4.00 (16H, m, -CO-O-CH2-CH3); 2.43-2.36 
(16H, m, -NH-CH-CH2-CH2-COOEt); 2.26-2.06 (6H, m, -NH-CH-CH2-CH2-COO-); 
2.04-1.81 (6H, m, -NH-CH-CH2-CH2-COO-); 1.23-1.108 (24H, m, -CO-O-CH2-CH3). 
13C NMR  (200 MHz, DMSO): δ 172.9, 172.6, 172.4, 169.8, 135.0, 132.1, 130.0, 
128.7, 61.3, 60.7, 54.5, 52.0, 35.5, 32.7, 30.6, 28.9, 26.8, 14.7. 
IR (KBr, cm-1): 3433, 3322, 3055, 2978, 2922, 2355, 2333, 1744, 1733, 1716, 
1698, 1681, 1651, 1602, 1558, 1540, 1523, 1402, 1276, 1200, 1171, 722, 672. 
mp = 124 °C 
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